Patent application title: P13 Kinase Antagonists
Inventors:
Zachary A. Knight (San Francisco, CA, US)
Olusegun Williams (San Francisco, CA, US)
Kevan M. Shokat (San Francisco, CA, US)
Kevan M. Shokat (San Francisco, CA, US)
Assignees:
REGENTS OF THE UNIVERSITY OF CALIFORNIA
IPC8 Class: AA61K31519FI
USPC Class:
5142621
Class name: Polycyclo ring system having 1,3-diazine as one of the cyclos bicyclo ring system having the 1,3-diazine as one of the cyclos exactly four ring nitrogens in the bicyclo ring system
Publication date: 2009-10-29
Patent application number: 20090270426
Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
Usenet FAQ Index |
Documents |
Other FAQs |
Patent application title: P13 Kinase Antagonists
Inventors:
Zachary A. Knight
Olusegun Williams
Kevan M. Shokat
Agents:
TOWNSEND AND TOWNSEND AND CREW, LLP
Assignees:
Regents of the University of California
Origin: SAN FRANCISCO, CA US
IPC8 Class: AA61K31519FI
USPC Class:
5142621
Patent application number: 20090270426
Abstract:
The present invention provides novel PI3-Kinase antagonists and methods of
use thereof.Claims:
1. A compound having the formula: ##STR00039## whereinq is an integer from
0 to 5;z is an integer from 0 to 10;X is ═CH-- or ═N--;L1 is
a bond, substituted or unsubstituted alkylene, substituted or
unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene,
substituted or unsubstituted heterocycloalkylene, substituted or
unsubstituted arylene, or substituted or unsubstituted
heteroarylene;R1 and R2 are independently halogen, --CN,
--OR5, --S(O)nR6, --NR7R8, --C(O)R9,
substituted or unsubstituted alkyl, substituted or unsubstituted
heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl, wherein n is independently an
integer from 0 to 2;R3, and R4 are independently hydrogen,
halogen, --CN, --OR5, --S(O)nR6, --NR7R8,
--C(O)R9, substituted or unsubstituted alkyl, substituted or
unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted heterocycloalkyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl;R5 is
independently hydrogen, --C(O)R10, substituted or unsubstituted
alkyl, substituted or unsubstituted heteroalkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,
substituted or unsubstituted aryl, or substituted or unsubstituted
heteroaryl;R6 is independently hydrogen, --NR11R12,
substituted or unsubstituted alkyl, substituted or unsubstituted
heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl, wherein if n is 1 or 2 then
R6 is other than hydrogen;R7 is independently hydrogen,
substituted or unsubstituted alkyl, substituted or unsubstituted
heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl;R8 is independently
hydrogen, --S(O)nR13, --C(O)R14, substituted or
unsubstituted alkyl, substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted
heterocycloalkyl, substituted or unsubstituted aryl, or substituted or
unsubstituted heteroaryl;R9 is independently --NR15R16,
hydrogen, substituted or unsubstituted alkyl, substituted or
unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted heterocycloalkyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl;R10
is independently hydrogen, --NR17R18, substituted or
unsubstituted alkyl, substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted
heterocycloalkyl, substituted or unsubstituted aryl, or substituted or
unsubstituted heteroaryl;R14 is independently hydrogen,
--NR19R20, substituted or unsubstituted alkyl, substituted or
unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted heterocycloalkyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl;
andR11, R12, R13, R15, R16, R17, R18,
R19, R20 are independently hydrogen, substituted or
unsubstituted alkyl, substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted
heterocycloalkyl, substituted or unsubstituted aryl, or substituted or
unsubstituted heteroaryl.
2. The compound of claim 1, wherein R1 is halogen, substituted or unsubstituted halo(C1-C6)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl(C1-C6)alkyl, or substituted or unsubstituted heteroaryl(C1-C6)alkyl.
3. The compound of claim 1, wherein R1 is halogen, substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted thiophenyl, or substituted or unsubstituted benzothiophenyl, substituted or unsubstituted indolyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted 1H-pyrrolo[2,3-c]pyridinyl, substituted or unsubstituted 1H-pyrrolo[2,3-b]pyridinyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted cylcohexyl, substituted or unsubstituted morpholino, substituted or unsubstituted piperidinyl, or substituted or unsubstituted tetrahydropyridinyl.
4. The compound of claim 3, wherein R1 is phenyl, furanyl, pyrrolyl, thiophenyl, or benzothiophenyl, each of which are optionally substituted with one or more R21 substituent(s), wherein R21 is independently(1) halogen, --CN, --OR22--C(O)R23, --NR24R25, --S(O)wNR26R27, or --S(O)wR28, wherein w is an integer from 0 to 2, and R22, R23, R24, R25, R26, R27, and R28 are independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyl-alkyl, heterocycloalkyl-alkyl, arylalkyl, or heteroarylalkyl, optionally substituted with unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl; or(2) (C1-C10)alkyl, 2 to 10 membered heteroalkyl, C3-C8 cycloalkyl, 3 to 8 membered heterocycloalkyl, aryl or heteroaryl optionally substituted with halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl.
5. The compound of claim 4, wherein R1 phenyl substituted at the meta and para positions, or substituted at the meta and meta positions.
6. The compound of claim 5, wherein R21 is halogen or --OR.sup.22.
7. The compound of claim 6, wherein R21 is fluorine and R22 is hydrogen or methyl.
8. The compound of claim 1, wherein q is 1.
9. The compound of claim 1, wherein z is 1.
10. The compound of claim 1, wherein R2 is halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl.
11. The compound of claim 1, wherein R2 is halogen or unsubstituted alkyl.
12. The compound of claim 1, wherein R2 is fluorine or unsubstituted C1-C4 alkyl.
13. The compound of claim 1, wherein R3 is halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl.
14. The compound of claim 1, wherein R3 is unsubstituted alkyl.
15. The compound of claim 1, wherein R3 is unsubstituted C1-C4 alkyl.
16. The compound of claim 1, wherein R4 is halogen, --OH, --CN, --NH2, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyl-alkyl, heterocycloalkyl-alkyl, arylalkyl, or heteroarylalkyl.
17. The compound of claim 1, wherein R2 and R3 are independently unsubstituted C1-C4 alkyl; R4 is NH2; q is 1; and z is 1.
18. The compound of claim 1, wherein L1 is substituted or unsubstituted alkylene.
19. The compound of claim 1, wherein L1 is substituted or unsubstituted alkynylene.
20. The compound of claim 1, wherein L1 is substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, substituted or unsubstituted ethynylene, or substituted or unsubstituted prop-2-ynylene.
21. The compound of claim 20, wherein R1 is --CN, --OR5, --NR7R8, R21-substituted or unsubstituted cycloalkyl, R21-substituted or unsubstituted aryl, R21-substituted or unsubstituted heteroaryl, R2-substituted or unsubstituted C1-C4 alkyl, whereinR21 is halogen, --OR22, --NR24R25, or unsubstituted C1-C4 alkyl andR5, R7, R8, R22, R24 and R25 are independently hydrogen or unsubstituted C1-C4 alkyl.
22. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
23. A method of decreasing the catalytic activity of a PI3-Kinase, the method comprising the step of contacting said PI3-Kinase with an activity decreasing amount of a PI3-Kinase affinity pocket binding antagonist.
24. The method of claim 23, wherein said antagonist is a PI3-Kinase affinity pocket quinazolinone antagonist.
25. The method of claim 23, wherein the PI3-Kinase is p110 δ kinase.
26. A method of decreasing the catalytic activity of a PI3-Kinase, the method comprising the step of contacting said PI3-Kinase with an activity decreasing amount of a compound having the formula: ##STR00040## whereinq is an integer from 0 to 5;z is an integer from 0 to 10;X is ═CH-- or ═N--;L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;R1 and R2 are independently halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein n is independently an integer from 0 to 2;R3, and R4 are independently hydrogen, halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R5 is independently hydrogen, --C(O)R10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R6 is independently hydrogen, --NR11R12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if n is 1 or 2 then R6 is other than hydrogen;R7 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R8 is independently hydrogen, --S(O)nR13, --C(O)R14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R9 is independently --NR15R16, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R10 is independently hydrogen, --NR17R18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R14 is independently hydrogen, --NR19R20, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; andR11, R12, R13, R15, R16, R17, R18R19, and R20 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
27. A method of treating a disease mediated by p110 δ kinase activity in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a PI3-Kinase affinity pocket binding antagonist.
28. The method of claim 27, wherein said antagonist is a PI3-Kinase affinity pocket quinazolinone antagonist.
29. The method of claim 27, wherein the disease is a hematologic malignancy, inflammation, autoimmune disease, or cardiovascular disease.
30. The method of claim 27, wherein the disease is a hematologic malignancy, or autoimmune disease.
31. The method of claim 27, wherein the disease is acute myelogenous leukemia, chronic myelogenous leukemia, mastocytosis, chronic lymphocytic leukemia, multiple myeloma, or myelodysplastic syndrome.
32. The method of claim 27, wherein the disease is rheumatoid arthritis, systemic lupus erythematosus, or asthma.
33. A method of treating a disease mediated by p110 δ kinase activity in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound having the formula: ##STR00041## whereinq is an integer from 0 to 5;z is an integer from 0 to 10;X is ═CH-- or ═N--;L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;R1 and R2 are independently halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein n is independently an integer from 0 to 2;R3, and R4 are independently hydrogen, halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R5 is independently hydrogen, --C(O)R10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R6 is independently hydrogen, --NR11R12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if n is 1 or 2 then R6 is other than hydrogen;R7 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R8 is independently hydrogen, --S(O)nR13, --C(O)R14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R9 is independently --NR15R16, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R10 is independently hydrogen, --NR17R18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R14 is independently hydrogen, --NR19R20, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; andR11, R12, R13, R15, R16, R17, R18, R19, and R20 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
34. A method of disrupting the function of a leukocyte or disrupting a function of an osteoclast, said method comprising contacting said leukocyte or said osteoclast with a function disrupting amount of a PI3-Kinase affinity pocket binding antagonist.
35. The method of claim 34, wherein said antagonist is a PI3-Kinase affinity pocket quinazolinone antagonist.
36. A method of disrupting the function of a leukocyte or disrupting a function of an osteoclast, said method comprising contacting said leukocyte or said osteoclast with a function disrupting amount of a compound having the formula ##STR00042## whereinq is an integer from 0 to 5;z is an integer from 0 to 10;X is ═CH-- or ═N--;L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;R1 and R2 are independently halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein n is independently an integer from 0 to 2;R3, and R4 are independently hydrogen, halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R5 is independently hydrogen, --C(O)R10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R6 is independently hydrogen, --NR11R12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if n is 1 or 2 then R6 is other than hydrogen;R7 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R8 is independently hydrogen, --S(O)nR13--C(O)R14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R9 is independently --NR15R16, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R10 is independently hydrogen, --NR17R18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;R14 is independently hydrogen, --NR19R20, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; andR11, R12, R13, R15, R16, R17, R18, R19, and R20 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
Description:
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001]This application is a continuation of U.S. patent application Ser. No. 11/732,857, filed Apr. 4, 2007, which claims the benefit of U.S. Provisional Patent Application No. 60/744,269, filed Apr. 4, 2006, and U.S. Provisional Patent Application No. 60/744,270, filed Apr. 4, 2006, all of which are incorporated herein by reference in their entireties and for all purposes.
BACKGROUND OF THE INVENTION
[0003]Phosphoinositide 3-kinases (PI3-Ks) catalyze the synthesis of the phosphatidylinositol (PI) second messengers PI(3)P, PI(3,4)P2, and PI(3,4,5)P3 (PIP3) (Fruman et al., 1998). In the appropriate cellular context, these three lipids control diverse physiological processes including cell growth, survival, differentiation and chemotaxis (Katso et al., 2001). The PI3-K family comprises 15 kinases with distinct substrate specificities, expression patterns, and modes of regulation (Katso et al., 2001). The class I PI3-Ks (p110α, p110β, p110 δ, and p110γ) are activated by tyrosine kinases or G-protein coupled receptors to generate PIP3, which engages downstream effectors such as the Akt/PDK1 pathway, the Tec family kinases, and the Rho family GTPases. The class II and III PI3-Ks play a key role in intracellular trafficking through the synthesis of PI(3)P and PI(3,4)P2. The PIKKs are protein kinases that control cell growth (mTORC1) or monitor genomic integrity (ATM, ATR, DNA-PK, and hSmg-1).
[0004]The importance of these enzymes in diverse pathophysiology has made the PI3-K family the focus of intense interest as a new class of drug targets (Ward et al., 2003). This interest has been fueled by the recent discovery that p110α is frequently mutated in primary tumors (Samuels et al., 2004) and evidence that the lipid phosphatase PTEN, an inhibitor of PI3-K signaling, is a commonly inactivated tumor suppressor (Cantley and Neel, 1999). Efforts are underway to develop small molecule PI3-K inhibitors for the treatment of inflammation and autoimmune disease (p110 δ, p110γ, and mTOR), thrombosis (p110β), viral infection (the PIKKs) and cancer (p110α, mTOR, and others). Recently, the first selective inhibitors of these enzymes have been reported (Camps et al., 2005; Condliffe et al., 2005; Jackson et al., 2005; Knight et al., 2004; Lau et al., 2005; Sadhu et al., 2003).
[0005]The present invention meets these and other needs in the art by providing a new class of PI3-Kinase antagonists.
BRIEF SUMMARY OF THE INVENTION
[0006]The present invention provides certain novel compounds found to be effective as antagonists of PI3-Kinases.
[0007]In one aspect, the present invention provides a PI3-Kinase affinity pocket binding antagonist (e.g. a PI3-Kinase affinity pocket quinazolinone antagonist) or a PI3-kinase antagonist as set forth in Formula (I), defined below.
[0008]In another aspect, the present invention provides methods of decreasing the catalytic activity of a PI3-Kinase. The method includes the step of contacting the PI3-Kinase with an activity decreasing amount of a PI3-Kinase affinity pocket binding antagonist (e.g. a PI3-Kinase affinity pocket quinazolinone antagonist) or a PI3-Kinase antagonist of Formula (I).
[0009]In another aspect, the present invention provides methods of treating disease mediated by treating a condition mediated by PI3-Kinase activity in a subject in need of such treatment. The method includes administering to the subject a therapeutically effective amount of a PI3-Kinase affinity pocket binding antagonist (e.g. a PI3-Kinase affinity pocket quinazolinone antagonist) or a PI3-Kinase antagonist of Formula (I).
[0010]In another aspect, the present invention provides methods of disrupting the function of a leukocyte or disrupting a function of an osteoclast. The method includes contacting the leukocyte or the osteoclast with a function disrupting amount of a PI3-Kinase affinity pocket binding antagonist (e.g. a PI3-Kinase affinity pocket quinazolinone antagonist) or a PI3-Kinase antagonist of Formula (I).
BRIEF DESCRIPTION OF THE DRAWINGS
[0011]FIG. 1 illustrates structures of representative compounds from eleven chemotypes of PI3-K inhibitors.
[0012]FIG. 2 illustrates structures of isoform-selective PI3-K inhibitors. A. Structure of ATP in the active site of p110γ, highlighting different regions of the ATP binding pocket. B. An alignment of all reported PI3-K inhibitor co-crystal structures. Met 804 adopts an up conformation in all structures except PIK-39. C. Structures or models of isoform-selective PI3-K inhibitors bound to p110γ. D. Structures or models of multi-targeted PI3-K inhibitors bound to p110γ.
[0013]FIG. 3 illustrates the probing of selectivity and an the PI3-Kinase affinity pocket. A. The structure of PIK-39 bound to p110γ suggests a model for the binding of IC87114. PIK-293 and PIK-294 are pyrazolopyrimidine analogs of IC87114. PIK-294 projects a m-phenol into the affinity pocket, and this compound is more potent against the class I PI3-Ks. B. (Left) Ratio of IC50 values between mutant and wild-type for p110 δ inhibitors and p110α/multi-targeted inhibitors. (Center) Dose response curves for binding of two p110 δ inhibitors to wild-type, M752I, and M752V p110 δ (Right) Models suggesting the impact of the M752I and M752V mutations in p110 δ on the binding of the different classes of inhibitors.
[0014]FIG. 4. Structures of additional PI3-K inhibitors and inactive analogs.
[0015]FIG. 5. IC50 values (μM) for selected PI3-K inhibitors against lipid kinases.
[0016]FIG. 6. Inhibition of protein kinases by PI3-K inhibitors. Values represent % activity remaining in the presence of 10 μM inhibitor. Values are average of triplicate measurements. IC50 values are in parenthesis where appropriate (μM).
[0017]FIG. 7 sets forth the sequence of a human p110 δ kinase (SEQ ID NO:1).
[0018]FIG. 8 sets forth the sequence of a human p110γ kinase (SEQ ID NO:2).
[0019]FIG. 9 sets forth the sequence of a human p110α kinase (SEQ ID NO:3).
[0020]FIG. 10 sets forth the sequence of a human p110β kinase (SEQ ID NO:4).
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
[0021]Abbreviations used herein have their conventional meaning within the chemical and biological arts.
[0022]Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., --CH2O-- is equivalent to --OCH2--.
[0023]The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e. unbranched) or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. C1-C10 means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
[0024]The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkyl, as exemplified, but not limited, by --CH2CH2CH2CH2--, --CH2CH═CHCH2--, --CH2C≡CCH2--, --CH2CH2CH(CH2CH2CH3)CH2--. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. An "alkynylene" is a subset of an alkylene in which the alkylene includes at least on triple bond between adjacent carbon atoms.
[0025]The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of at least one carbon atoms and at least one heteroatom selected from the group consisting of O, N, P, Si and S, and wherein the nitrogen, phosphorus, and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N, P and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, --CH2--CH2--O--CH3, --CH2--CH2--NH--CH3, --CH2--CH2--N(CH3)--CH3, --CH2--S--CH2--CH3, --CH2--CH2, --S(O)--CH3, --CH2--CH2--S(O)2--CH3, --CH═CH--O--CH3, --Si(CH3)3, --CH2--CH═N--OCH3, --CH═CH--N(CH3)--CH3, O--CH3, --O--CH2--CH3, and --CN. Up to two or three heteroatoms may be consecutive, such as, for example, --CH2--NH--OCH3 and --CH2--O--Si(CH3)3. Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, --CH2--CH2--S--CH2--CH2-- and --CH2--S--CH2--CH2--NH--CH2--. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxo, alkylenedioxo, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula --C(O)OR'-represents both --C(O)OR'-- and --R'OC(O)--. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as --C(O)R', --C(O)NR', --NR'R'', --OR', --SR', and/or --SO2R'. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as --NR'R'' or the like, it will be understood that the terms heteroalkyl and --NR'R'' are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as --NR'R'' or the like.
[0026]The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. The terms "cycloalkylene" and "heterocycloalkylene" refer to the divalent derivatives of cycloalkyl and heterocycloalkyl, respectively.
[0027]The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0028]The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four heteroatoms (in each separate ring in the case of multiple rings) selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. The terms "arylene" and "heteroarylene" refer to the divalent radicals of aryl and heteroaryl, respectively.
[0029]For brevity, the term "aryl" when used in combination with other terms (e.g., aryloxo, arylthioxo, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like). However, the term "haloaryl," as used herein is meant to cover only aryls substituted with one or more halogens.
[0030]Where a heteroalkyl, heterocycloalkyl, or heteroaryl includes a specific number of members (e.g. "3 to 7 membered"), the term "member" referrers to a carbon or heteroatom.
[0031]The term "oxo" as used herein means an oxygen that is double bonded to a carbon atom.
[0032]Each of above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl, and "heterocycloalkyl", "aryl," "heteroaryl" as well as their divalent radical derivatives) are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
[0033]Substituents for alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl monovalent and divalent derivative radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to: --OR', ═O, ═NR', ═N--OR', --NR'R'', --SR', -halogen, --SiR'R''R''', --OC(O)R', --C(O)R', --CO2R', --C(O)NR'R'', --OC(O)NR'R'', --NR''C(O)R', --NR'--C(O)NR''R''', --NR''C(O)OR', --NR--C(NR'R'')═NR''', --S(O)R', --S(O)2R', --S(O)2NR'R'', --NRSO2R', --CN and --NO2 in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'', R''' and R'''' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. As used herein, an "alkoxy" group is an alkyl attached to the remainder of the molecule through a divalent oxygen radical. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, --NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., --CF3 and --CH2CF3) and acyl (e.g., --C(O)CH3, --C(O)CF3, --C(O)CH2OCH3, and the like).
[0034]Similar to the substituents described for alkyl radicals above, exemplary substituents for aryl and heteroaryl groups (as well as their divalent derivatives) are varied and are selected from, for example: halogen, --OR', --NR'R'', --SR', -halogen, --SiR'R''R''', --OC(O)R', --C(O)R', --CO2R', --C(O)NR'R'', --OC(O)NR'R'', --NR''C(O)R', --NR'--C(O)NR''R''', --NR''C(O)OR', --NR--C(NR'R''R''')--NR'''', --NR--C(NR'R'')═NR''', --S(O)R', --S(O)2R', --S(O)2NR'R'', --NRSO2R', --CN and --NO2, --R', --N3, --CH(Ph)2, fluoro(C1-C4)alkoxo, and fluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on aromatic ring system; and where R', R'', R''' and R'''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present.
[0035]Two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)--(CRR')q--U--, wherein T and U are independently --NR--, --O--, --CRR'-- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r--B--, wherein A and B are independently --CRR'--, --O--, --NR--, --S--, --S(O)--, --S(O)2--, --S(O)2NR'-- or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula --(CRR')s--X'--(C''R''')d--, where s and d are independently integers of from 0 to 3, and X' is --O--, --NR'--, --S--, --S(O)--, --S(O)2--, or --S(O)2NR'--. The substituents R, R', R'' and R''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0036]As used herein, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
[0037]An "aminoalkyl" as used herein refers to an amino group covalently bound to an alkylene linker. The amino group is --NR'R'', wherein R' and R'' are typically selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0038]A "substituent group," as used herein, means a group selected from the following moieties:
[0039](A) --OH, --NH2, --SH, --CN, --CF3, --NO2, oxo, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
[0040](B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from:
[0041](i) oxo, --OH, --NH2, --SH, --CN, --CF3, --NO2, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
[0042](ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from:
[0043](a) oxo, --OH, --NH2, --SH, --CN, --CF3, --NO2, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
[0044](b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, substituted with at least one substituent selected from oxo, --OH, --NH2, --SH, --CN, --CF3, --NO2, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
[0045]A "size-limited substituent" or "size-limited substituent group," as used herein means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C4-C8 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 4 to 8 membered heterocycloalkyl.
[0046]A "lower substituent" or "lower substituent group," as used herein means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C5-C7 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl.
[0047]The compounds of the present invention may exist as salts. The present invention includes such salts. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures, succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art. Also included are base addition salts such as sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like. Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0048]The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0049]Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
[0050]Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)--or (S)-- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention. The compounds of the present invention do not include those which are known in art to be too unstable to synthesize and/or isolate. The present invention is meant to include compounds in racemic and optically pure forms. Optically active (R)--and (S)--, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
[0051]The term "tautomer," as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
[0052]It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.
[0053]Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
[0054]Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13C- or 14C-enriched carbon are within the scope of this invention.
[0055]The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
[0056]The term "pharmaceutically acceptable salts" is meant to include salts of active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituent moieties found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0057]In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0058]The terms "a," "an," or "a(n)", when used in reference to a group of substituents herein, mean at least one. For example, where a compound is substituted with "an" alkyl or aryl, the compound is optionally substituted with at least one alkyl and/or at least one aryl. Moreover, where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different.
[0059]Description of compounds of the present invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
[0060]The terms "treating" or "treatment" refers to any indicia of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. For example, the certain methods presented herein successfully treat cancer by decreasing the incidence of cancer and or causing remission of cancer.
[0061]An "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease. An "effective amount may also be referred to as a "therapeutically effective amount." A "reduction" of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A "prophylactically effective amount" of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) a disease, or reducing the likelihood of the onset (or reoccurrence) of a disease or its symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An "activity decreasing amount," as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A "function disrupting amount," as used herein, refers to the amount of antagonist required to disrupt the function of an osteoclast or leukocyte relative to the absence of the antagonist.
[0062]As used herein, the "antagonist" or "the compound of the present invention" refers to a compound of Formula (I), or a PI3-Kinase affinity pocket binding antagonist (e.g. a PI3-Kinase affinity pocket quinazolinone antagonist). A "compound of Formula (I)" includes all embodiments of Formula (I) as described below.
II. PI3-Kinase Antagonists
[0063]In one aspect, the present invention provides novel PI3-kinase antagonists. In some embodiments, the PI3-kinase antagonist is a PI3-Kinase affinity pocket binding antagonist (e.g. a PI3-Kinase affinity pocket quinazolinone antagonist). The PI3-Kinase affinity pocket binding antagonist of the present invention is a compound containing a PI3-Kinase affinity pocket binding moiety. The PI3-Kinase affinity pocket quinazolinone antagonists of the present invention are substituted quinazolinone compounds containing a PI3-Kinase affinity pocket binding moiety. The PI3-Kinase affinity pocket binding moiety is a substituent which, upon contacting a p110α, p110β, p110γ, or p110 δ kinase, fills space within the corresponding PI3-Kinase affinity pocket. In some embodiments, the PI3-Kinase affinity pocket binding moiety displaces at least one water molecule within the PI3-Kinase affinity pocket. The PI3-Kinase affinity pocket binding moiety may also interact with one or more amino acids that from part of the PI3-Kinase affinity pocket. A description of the PI3-Kinase affinity pocket and methods of determining whether a substituent fills space within the PI3-Kinase affinity pocket are set forth below.
[0064]In some embodiments, the PI3-Kinase affinity pocket quinazolinone antagonist further include a pyrazolopyrimidine substituent or a pyrrolopyrimidine substituent. In some related embodiments, the pyrazolopyrimidine substituent or pyrrolopyrimidine substituent is covalently bonded to the quinazolinone core, and the PI3-Kinase affinity pocket binding moiety is covalently attached to the pyrazolopyrimidine substituent or pyrrolopyrimidine substituent.
[0065]In some embodiments, the PI3-kinase antagonist of the present invention has the formula:
##STR00001##
[0066]In Formula (I) above, q is an integer from 0 to 5 (e.g. 1); z is an integer from 0 to 10 (e.g. 1); and X is ═CH-- or ═N--. L1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
[0067]R1 and R2 are independently halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, where n is an integer from 0 to 2. R1 may also be a PI3-Kinase affinity pocket binding moiety. R3 and R4 are independently hydrogen, halogen, --CN, --OR5, --S(O)nR6, --NR7R8, --C(O)R9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, where n is an integer from 0 to 2.
[0068]R5 is independently hydrogen, --C(O)R10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R6 is independently hydrogen, --NR11R12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. Where n is 1 or 2, R6 is other than hydrogen.
[0069]R7 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R8 is independently hydrogen, --S(O)nR13, --C(O)R14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0070]R9 is independently --NR15R16, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R10 is independently hydrogen, --NR17R18, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0071]R14 is independently hydrogen, --NR19R20, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
[0072]R11, R12, R13, R15, R16, R17, R18, R19, and R20 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0073]In some embodiments, the PI3-Kinase affinity pocket binding moiety is capable of forming a hydrogen bond with the side chain amine of K833, an amino acid within the PI3-Kinase affinity pocket.
[0074]In some embodiments, R1 is halogen, substituted or unsubstituted halo(C1-C6)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl(C1-C6)alkyl, or substituted or unsubstituted heteroaryl(C1-C6)alkyl. R1 may also be halogen, substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted thiophenyl, or substituted or unsubstituted benzothiophenyl, substituted or unsubstituted indolyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted 1H-pyrrolo[2,3-c]pyridinyl, substituted or unsubstituted 1H-pyrrolo[2,3-b]pyridinyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted cylcohexyl, substituted or unsubstituted morpholino, substituted or unsubstituted piperidinyl, or substituted or unsubstituted tetrahydropyridinyl.
[0075]In other embodiments, R1 is phenyl, furanyl, pyrrolyl, thiophenyl, or benzothiophenyl, each of which are optionally substituted with one or more R21 substituent(s). R21 is independently (1) or (2) as defined in this paragraph. Thus, R21 may be (1) halogen, --CN, --OR22, --C(O)R23, --NR24R25, --S(O)wNR26R27, or --S(O)wR28. The symbol w is an integer from 0 to 2. R22, R23, R24, R25, R26, R27, and R28 are independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyl-alkyl, heterocycloalkyl-alkyl, arylalkyl, or heteroarylalkyl, optionally substituted with unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl. R21 may also be (2) (C1-C10)alkyl, 2 to 10 membered heteroalkyl, C3-C8 cycloalkyl, 3 to 8 membered heterocycloalkyl, aryl or heteroaryl optionally substituted with halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl.
[0076]In some embodiments, R1 is phenyl substituted at the meta and para positions, or substituted at the meta and meta positions. That is, R1 is a 4,5-substituted phenyl or a 3,5-substituted phenyl. In some related embodiments, the 4,5-substituted phenyl or 3,5-substituted phenyl is substituted, independently, with R21 (as defined in the previous paragraph). In some embodiments, R21 is halogen or --OR22. R21 may also be fluorine and R22 may be hydrogen or unsubstituted C1-C4 alkyl (e.g. methyl). In other embodiments, R1 is phenyl substituted para position (i.e. a 4-substituted phenyl).
[0077]In some embodiments, L1 is substituted or unsubstituted alkylene (e.g. a substituted or unsubstituted alkynylene. In other embodiments, L1 is substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylenes, substituted or unsubstituted ethynylene, or substituted or unsubstituted prop-2-ynylene. In some related embodiments, R1 is --CN, --OR5, NR7R8, R21-substituted or unsubstituted cycloalkyl, R21-substituted or unsubstituted aryl, R21-substituted or unsubstituted heteroaryl, R21-substituted or unsubstituted C1-C4 alkyl. R21 may be halogen, --OR22, --NR24R25, or unsubstituted C1-C4 alkyl. R5, R7, R8, R22, R24 and R25 may independently be hydrogen or unsubstituted C1-C4 alkyl (e.g. methyl).
[0078]In some embodiments, R2 is halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl. R2 may also be halogen or unsubstituted alkyl. In some embodiments, R2 is fluorine or unsubstituted C1-C4 alkyl (e.g. methyl).
[0079]R3 may be halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl. R3 may also be unsubstituted C1-C4 alkyl (e.g. methyl).
[0080]In some embodiments, R4 is halogen, --OH, --CN, --NH2, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted cycloalkyl-alkyl, unsubstituted heterocycloalkyl-alkyl, unsubstituted arylalkyl, or unsubstituted heteroarylalkyl.
[0081]In some embodiments, R2 and R3 are independently unsubstituted C1-C4 alkyl, R4 is NH2, q is 1, and z is 1.
[0082]In some embodiments, each substituted group described above in the compound of Formula (I) is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted cycloalkyl-alkyl, substituted heterocycloalkyl-alkyl, substituted arylalkyl, and/or substituted heteroarylalkyl, described above in the compounds of Formula (I) is substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. Alternatively, at least one or all of these groups are substituted with at least one lower substituent group.
[0083]In other embodiments of the compounds of Formula (I), each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, including those alkyl groups forming part of a cycloalkyl-alkyl (i.e. a cycloalkyl-(C1-C20)alkyl), heterocycloalkyl-alkyl (i.e. a heterocycloalkyl-(C1-C20)alkyl), arylalkyl (i.e. an aryl-(C1-C20)alkyl), or substituted heteroarylalkyl (i.e. a heteroaryl-(C1-C20)alkyl). Each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl. Each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C4-C8 cycloalkyl, including those cycloalkyl groups forming part of a cycloalkyl-alkyl (i.e. a C4-C8 cycloalkyl-alkyl, or a C4-C8 cycloalkyl-(C1-C20)alkyl). Each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 4 to 8 membered heterocycloalkyl, including those heterocycloalkyl groups forming part of a heterocycloalkyl-alkyl (i.e. a 4 to 8 membered heterocycloalkyl-alkyl, or a 4 to 8 membered heterocycloalkyl-(C1-C20)alkyl).
[0084]Alternatively, each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C5-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl, including cycloalkyl-alkyl groups, heterocycloalkyl-alkyl groups, heteroarylalkyl groups, and arylalkyl groups, as described in the preceding paragraph.
[0085]In another embodiment, the compounds of the present invention include the compounds of any one or all of those listed in Table 1 below.
III. The PI3-Kinase Affinity Pocket
[0086]The term "PI3-Kinase affinity pocket," as used herein, refers to a cavity within p110α, p110β, p110γ, and p110 δ corresponding to the lightly shaded region shown in FIGS. 2A, 2C, and 2D labeled "Affinity Pocket." FIGS. 2A, 2C, and 2D illustrate a computer model of the p110γ crystal structure. In p110γ, the surface of the PI3-Kinase affinity pocket is bound, at least in part, by the side chain of K833, D964, I879, and D841 (p110γ numbering, see FIG. 8). The surface of the corresponding cavity in p110 δ is bound, at least in part, by the side chain of K779, D911, I825, and D787 (p110 δ numbering, see FIG. 7). The corresponding cavity within p110α is bound, at least in part, by the side chains of K802, D933, I848, and D810 (p110α numbering, see FIG. 9). The corresponding cavity within p110β is bound, at least in part, by the side chains of K805, D937, I851, and D813 (p110β numbering, see FIG. 10). The PI3-Kinase affinity pocket is not accessed by ATP.
[0087]The PI3-Kinase affinity pocket of p110 δ may be referred to herein as the p110 δ affinity pocket. Likewise, the PI3-Kinase affinity pocket of p110γ may be referred to herein as the p110γ affinity pocket. The PI3-Kinase affinity pocket includes lysine 779, which, according to computer models, forms a hydrogen bond with the pyridine nitrogen of PIK-90 and the phenol oxygen of PI 103 (FIG. 2D), both of which are inhibitors of p110 δ. Based on these computer modeling results, a novel antagonist was designed based on the chemical structure of PIK-39 and IC87114, as detailed below.
[0088]As shown in FIG. 2C, PIK-39 does not contain a PI3-Kinase binding pocket moiety. And as shown in FIG. 3A, IC87114 maintains contacts to E880 and V882 in the ATP binding region of p110 δ, but is also missing a PI3-Kinase binding pocket moiety. By inserting m-phenol (a PI3-Kinase binding pocket moiety) at the C3 of the pyrazolopyrimidine of IC87114, the PI3-Kinase affinity pocket is accessed (FIG. 3A) resulting in a 60-fold increase in p110 δ inhibition potency.
[0089]As described above, a PI3-Kinase binding pocket moiety is a substituent which, upon contacting upon contacting p110α, p110β, p110γ, or p110 δ, fills space within the corresponding PI3-Kinase binding pocket. For example, a PI3-Kinase affinity pocket binding moiety is a substituent which, upon contacting upon contacting p110 δ, fills space within the p110 δ affinity pocket. Likewise, a p110α affinity pocket binding moiety is a substituent which, upon contacting upon contacting p110α, fills space within the p110α affinity pocket. In some embodiments, the antagonist interact with or displaces the side chain of methionine 804 of p110γ, or the equivalent methionine present in p110α, p110β, or p110α (See FIGS. 7-10).
[0090]In some embodiments, the PI3-Kinase binding pocket moiety additionally interacts (e.g. bonds) with an amino acid that forms part of the PI3-Kinase binding pocket. In some related embodiments, the interaction is a hydrogen bond, van der Waals interaction, ionic bond, covalent bond (e.g. disulfide bond) or hydrophobic interaction.
IV. Determining Space Filling Within the PI3-Kinase Affinity Pocket
[0091]To determine whether the PI3-Kinase affinity pocket binding moiety fills space within the PI3-Kinase affinity pocket, computer modeling techniques are employed. A query PI3-Kinase affinity pocket binding antagonist (i.e. a test compound) is fit into a computer image of p110γ. The p110γ computer image is derived from the solved co-crystal structure of human p110γbound to PIK-39. The PyMOL Molecular Graphics System may be employed to generate the image. An example is presented in FIG. 3A, wherein IC87114 and PIK-294 are built into the computer image of p110γ kinase, derived from the p110γ-PIK-39 co-crystal. See Knight, et al., Cell 125: 733-745 (2006).
[0092]The computer models are typically analyzed to prevent any gross steric clashes and to satisfy key hydrogen bonds between the query PI3-Kinase affinity pocket binding antagonist and the p110γ protein (e.g. V882 and M804). In some embodiments, energy minimization calculations are performed to optimize binding energy. Using these techniques, one skilled in the art can easily determine whether a query PI3-Kinase affinity pocket binding antagonist includes a PI3-Kinase affinity pocket binding moiety that fills space within the PI3-Kinase affinity pocket.
[0093]In some embodiments, the query PI3-Kinase affinity pocket binding antagonist is analyzed to determine whether at least one bond (e.g. a hydrogen bond) is formed between the query PI3-Kinase affinity pocket binding antagonist and an amino acid that form part of the PI3-Kinase affinity pocket. Using a computer modeling technique as described above, the distance between one or more amino acids that form part of the PI3-Kinase affinity pocket and a potential contact point on the PI3-Kinase affinity pocket binding moiety is determined. Based on this distance, one skilled in the art may determine whether at least one bond is formed between one or more amino acids that form part of the PI3-Kinase affinity pocket and a PI3-Kinase affinity pocket binding moiety.
V. General Syntheses
[0094]The compounds of the invention are synthesized by an appropriate combination of generally well known synthetic methods. Techniques useful in synthesizing the compounds of the invention are both readily apparent and accessible to those of skill in the relevant art. The discussion below is offered to illustrate certain of the diverse methods available for use in assembling the compounds of the invention. However, the discussion is not intended to define the scope of reactions or reaction sequences that are useful in preparing the compounds of the present invention.
##STR00002##
[0095]In Scheme 1, R1, R2, R3, X, and q are as defined above. The anthranilic acid E1 may be converted to the acid chloride using, for example, SOCl2 and then directly reacted with the amino functionality of an aniline to yield the corresponding amide E2. Subsequent cyclization of E2 may be accomplished using chloroacetylchloride. Substitution of the E3 chlorine with the iodo-pyrazolopyrimidine or iodo-pyrrolopyrimidine is performed in the presence of base to form E4. Finally, the iodine of E4 is substituted with R' by a Suzuki-Miyaura coupling with the appropriate boronic acid.
VI. Methods
[0096]In another aspect, the present invention provides methods of decreasing the catalytic activity of a PI3 kinase, such as p110 δ kinase or p110γ kinase. The method includes the step of contacting the PI3 kinase (e.g. p110 δ kinase) with an activity decreasing amount of a PI3-Kinase antagonist (i.e. a PI3-Kinase affinity pocket binding antagonist or a PI3-Kinase antagonist of Formula (I)). In some embodiments, the antagonist is a PI3-Kinase affinity pocket quinazolinone antagonist. In some embodiments, the PI3-Kinase antagonist is specific to p110 δ relative to the antagonist action against p110α, p110β, and/or p110γ. In some embodiments, the PI3-Kinase antagonist is specific to p110 δ relative to the antagonist action against p110α and/or p110β. In some embodiments, the PI3-Kinase antagonist is specific to p110 δ relative to the antagonist action against p110α. In some embodiments, the PI3-Kinase antagonist is specific to p110γ relative to the antagonist action against p110α and/or p110β. In some embodiments, the PI3-Kinase antagonist is specific to p110γ relative to the antagonist action against p110α.
[0097]In some embodiments, where the PI3-Kinase antagonist is specific to p110γ relative to the antagonist action against p110β, and/or p110α, the PI3-Kinase antagonist is the PI3-Kinase antagonist of Formula (I), where R1 is a 4,5-substituted phenyl. In some related embodiments, the 4,5-substituted phenyl is substituted, independently, with R21. R21 may be halogen or --OR22. R21 may also be fluorine and R22 may be hydrogen or unsubstituted C1-C4 alkyl (e.g. methyl).
[0098]In other embodiments, where the PI3-Kinase antagonist is specific to p110 δ relative to the antagonist action against p110α, p110β, and/or p110γ, the PI3-Kinase antagonist is the PI3-Kinase antagonist of Formula (I), where R' is a 3,5-substituted phenyl. In some related embodiments, the 3,5-substituted phenyl is substituted, independently, with R21. R21 may be halogen or --OR22. R21 may also be fluorine and R22 may be hydrogen or unsubstituted C1-C4 alkyl (e.g. methyl).
[0099]In some embodiments, the IC50 against the p110 δ kinase and/or p110γ is at least 1.5, 2.0, 3.0, 4.0, 5.0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, or 100 fold lower than the IC50 against p110α, and/or p110γ. In other embodiments, the IC50 of the antagonist against p110 δ kinase and/or p110γ is less than 100 μM, 50 μM, 40 μM, 30 μM, 20 μM, 10 μM, 5 μM, 1 μM, 0.5 μM, 0.1 μM, 50 nM, 10 nM, 1 nM. 0.5 nM, 0.1 nM, 50 pM, 10 pM, or 1 pM.
[0100]In another aspect, the present invention provides methods of treating a disease mediated by PI3-Kinase activity (e.g. p110γ kinase activity or p110γ kinase activity) in a subject in need of such treatment. The method includes administering to the subject a therapeutically effective amount of a PI3-Kinase antagonist (i.e. a PI3-Kinase affinity pocket antagonist or PI3-Kinase antagonist of Formula (I)). In some embodiments, the antagonist is a PI3-Kinase affinity pocket quinazolinone antagonist.
[0101]In some embodiments, the disease is a hematologic malignancy, inflammation, autoimmune disease, or cardiovascular disease. In some embodiments, the disease is a hematologic malignancy or autoimmune disease. Examples of hematologic malignancies include acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndrome (MDS). Examples of inflammation disorders and autoimmune disease include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and asthma. Other disorders include bone-resorption disorders and thromobsis.
[0102]The disorder may also be a type of cancer or cancer metastasis, including, for example, leukemia, carcinomas and sarcomas, such as cancer of the brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and medulloblastoma. Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine and exocrine pancreas, and prostate cancer. A detailed description of conditions and disorders mediated by p110 δ kinase activity is set forth in Sadu et al., WO 01/81346, which is incorporated herein by reference in its entirety for all purposes.
[0103]In another aspect, the present invention provides methods of disrupting the function of a leukocyte or disrupting a function of an osteoclast. The method includes contacting the leukocyte or the osteoclast with a function disrupting amount of a PI3-Kinase antagonist (i.e. a PI3-Kinase affinity pocket antagonist or PI3-Kinase antagonist of Formula (I)). In some embodiments, the antagonist is a PI3-Kinase affinity pocket quinazolinone antagonist.
VII. Pharmaceutical Formulations
[0104]In another aspect, the present invention provides a pharmaceutical composition including a PI3-Kinase affinity pocket binding antagonist or a compound of Formula (I) in admixture with a pharmaceutically acceptable excipient. One of skill in the art will recognize that the pharmaceutical compositions include the pharmaceutically acceptable salts of the PI3-Kinase antagonists of the present invention described above.
[0105]In therapeutic and/or diagnostic applications, the compounds of the invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington: The Science and Practice of Pharmacy (20th ed.) Lippincott, Williams & Wilkins (2000).
[0106]The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. A most preferable dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.
[0107]Pharmaceutically acceptable salts are generally well known to those of ordinary skill in the art, and may include, by way of example but not limitation, acetate, benzenesulfonate, besylate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, or teoclate. Other pharmaceutically acceptable salts may be found in, for example, Remington: The Science and Practice of Pharmacy (20th ed.) Lippincott, Williams & Wilkins (2000). Preferred pharmaceutically acceptable salts include, for example, acetate, benzoate, bromide, carbonate, citrate, gluconate, hydrobromide, hydrochloride, maleate, mesylate, napsylate, pamoate (embonate), phosphate, salicylate, succinate, sulfate, or tartrate.
[0108]Depending on the specific conditions being treated, such agents may be formulated into liquid or solid dosage forms and administered systemically or locally. The agents may be delivered, for example, in a timed- or sustained-low release form as is known to those skilled in the art. Techniques for formulation and administration may be found in Remington: The Science and Practice of Pharmacy (20th ed.) Lippincott, Williams & Wilkins (2000). Suitable routes may include oral, buccal, by inhalation spray, sublingual, rectal, transdermal, vaginal, transmucosal, nasal or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intra-articullar, intra-sternal, intra-synovial, intra-hepatic, intralesional, intracranial, intraperitoneal, intranasal, or intraocular injections or other modes of delivery.
[0109]For injection, the agents of the invention may be formulated and diluted in aqueous solutions, such as in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
[0110]Use of pharmaceutically acceptable inert carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject (e.g. patient) to be treated.
[0111]For nasal or inhalation delivery, the agents of the invention may also be formulated by methods known to those of skill in the art, and may include, for example, but not limited to, examples of solubilizing, diluting, or dispersing substances such as, saline, preservatives, such as benzyl alcohol, absorption promoters, and fluorocarbons.
[0112]Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0113]In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
[0114]Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethyl-cellulose (CMC), and/or polyvinylpyrrolidone (PVP: povidone). If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[0115]Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[0116]Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs). In addition, stabilizers may be added.
[0117]Depending upon the particular condition, or disease state, to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention. For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the inhibitors of this invention to treat proliferative diseases and cancer. Examples of known chemotherapeutic agents include, but are not limited to, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives.
[0118]Other examples of agents the inhibitors of this invention may also be combined with include, without limitation, anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; agents for treating diabetes such as insulin, insulin analogues, alpha glucosidase inhibitors, biguanides, and insulin sensitizers; and agents for treating immunodeficiency disorders such as gamma globulin.
[0119]These additional agents may be administered separately, as part of a multiple dosage regimen, from the inhibitor-containing composition. Alternatively, these agents may be part of a single dosage form, mixed together with the inhibitor in a single composition.
[0120]The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those having skill in the art from the foregoing description. Such modifications are intended to fall within the scope of the invention. Moreover, any one or more features of any embodiment of the invention may be combined with any one or more other features of any other embodiment of the invention, without departing from the scope of the invention. For example, the PI3-Kinase agonists of the present invention described above are equally applicable to the methods of treatment and methods of inhibiting kinases described herein. References cited throughout this application are examples of the level of skill in the art and are hereby incorporated by reference herein in their entirety for all purposes, whether previously specifically incorporated or not.
VIII. Examples
[0121]The following examples are meant to illustrate certain embodiments of the invention, and not to limit the scope of the invention.
[0122]A. Exemplary Synthesis Scheme
##STR00003## ##STR00004##
[0123]Scheme 2 illustrates synthetic routes to certain compounds listed in Table 1 below. Using the information provided in Schemes 1 and 2, and the detailed synthesis information of certain compounds provided below, one skilled in the art would immediately recognize the synthetic routes to the compounds of the present invention.
[0124]B. Detailed Synthesis of Certain Compounds
1. Synthesis of 2-amino-6-methyl-N-o-tolylbenzamide
[0125]2-amino-6-methylbenzoic acid (25 g, 165 mmol) was dissolved in benzene (250 mL). Thionyl chloride (37.5 mL, 500 mmol) was added and the reaction heated to reflux overnight. The following day the reaction was concentrated in vacuo, and then taken up twice in benzene (200 mL) and solvent removed in vacuo again to give a black oil. The oil was dissolved in CHCl3 (400 mL), o-toluidine (44 mL, 412 mmol) was added and the reaction heated to reflux. Reaction was complete after two hours, and the product was purified by three silica gel chromatographies (15% EtOAc/Hexanes) to yield a tan solid (29 g, 73.4% yield). LR-ESI MS (M+H).sup.+ m/z calcd 241.1, found 240.9.
2. Synthesis of 2-(chloromethyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one
[0126]Chloroacetylchloride (29 mL, 363 mmol) was added to a solution of 2-amino-6-methyl-N-o-tolylbenzamide (29 g, 121 mmol) in acetic acid (600 mL) and the reaction heated to reflux. After two hours the reaction was cooled to RT, and concentrated in vacuo. The product was purified by three silica gel chromatographies (twice in 15% EtOAc/Hexanes followed by 10% diethylether/hexanes) to yield a white solid (8.3 g, 23% yield). LR-ESI MS (M+H).sup.+ m/z calcd 299. 1, found 298.8.
3. Synthesis of 2-((4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl-3-o-tolylqu- inazolin-4(3H)-one
[0127]2-(chloromethyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one (0.15 g, 0.5 mmol) and 1H-pyrazolo[3,4-d]pyrimidin-4-amine (0.101 g, 0.05 mmol) were added to DMF (10 mL) and K2CO3 (0.138 g, 1 mmol) and allowed to stir at RT in the dark for 24 hours. The product was precipitated by addition of water (800 mL) and collected by filtration. The precipitate was further purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 398.2, found 398.1.
4. Synthesis of Compound S2
[0128]2-(chloromethyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one (3 g, 10.0 mmol) and 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.91 g, 15.05 mmol) were added to DMF (50 mL) and K2CO3 (2.77 g, 20 mmol) and allowed to stir at RT in the dark for 24 hours. The product was precipitated by addition of water (900 mL) and collected by filtration. The precipitate was further purified by silica gel chromatography (2% MeOH/CH2Cl2). LR-ESI MS (M+H).sup.+ m/z calcd 524.1, found 523.9.
5. Synthesis of Compound S3
[0129]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (50 mg, 0.096 mmol), m-phenol boronic acid (14.5 mg, 0.105 mmol) and tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol) were dissolved in a solution of DME (10 mL), EtOH (1.6 mL) and saturated aqueous Na2CO3 (2.75 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 490.2, found 490.1.
6. Synthesis of Compound S4
[0130]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (50 mg, 0.096 mmol), 5-formylbenzo[b]thiophene-2-boronic ester (30.3 mg, 0.105 mmol) and tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol) were dissolved in a solution of DME (10 mL), EtOH (1.6 mL) and saturated aqueous Na2CO3 (2.75 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 558.2, found 558.0.
7. Synthesis of Compound S5
[0131]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (50 mg, 0.096 mmol), 5-formyl-3-methylthiophene-2-boronic acid (18.9 mg, 0.105 mmol) and tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol) were dissolved in a solution of DME (10 mL), EtOH (1.6 mL) and saturated aqueous Na2CO3 (2.75 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 522.2, found 522.0.
8. Synthesis of S6
[0132]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (100 mg, 0.192 mmol), 3,4-dimethoxyphenyl boronic ester (38.2 mg, 0.21 mmol) and tetrakis(triphenylphosphine)palladium (44 mg, 0.038 mmol) were dissolved in a solution of DME (20 mL), EtOH (3.2 mL) and saturated aqueous Na2CO3 (5.5 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 534.2, found 534.0.
9. Synthesis of S7
[0133]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-o-tolylquinazolin-4(3H)-one (100 mg, 0.192 mmol), 4-phenoxyphenyl boronic acid (44.9 mg, 0.21 mmol) and tetrakis(triphenylphosphine)palladium (44 mg, 0.038 mmol) were dissolved in a solution of DME (20 mL), EtOH (3.2 mL) and saturated aqueous Na2CO3 (5.5 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 566.2, found 566.0.
10. Synthesis of S8
[0134]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (100 mg, 0.192 mmol), 4-benzyloxyphenyl boronic acid (47.9 mg, 0.21 mmol) and tetrakis(triphenylphosphine)palladium (44 mg, 0.038 mmol) were dissolved in a solution of DME (20 mL), EtOH (3.2 mL) and saturated aqueous Na2CO3 (5.5 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA).
11. Synthesis of S33
[0135]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (50 mg, 0.096 mmol), 3-cyanophenyl boronic acid (15.8 mg, 0.105 mmol) and tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol) were dissolved in a solution of DME (10 mL), EtOH (1.6 mL) and saturated aqueous Na2CO3 (2.75 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 499.2, found 499.0.
12. Synthesis of 2-amino-N-(2-chlorophenyl)-6-methylbenzamide
[0136]2-amino-6-methylbenzoic acid (2.5 g, 16.5 mmol) was dissolved in benzene (75 mL). Thionyl chloride (3.0 mL, 41.1 mmol) was added and the reaction heated to reflux overnight. The following day the reaction was concentrated in vacuo, and then taken up twice in benzene (75 mL) and solvent removed in vacuo again to give a black oil. The oil was dissolved in CHCl3 (75 mL), 2-chloroaniline (3.5 mL) was added and the reaction heated to reflux. Reaction was complete after four hours, at which point the reaction was filtered, the filtrate concentrated in vacuo, and the product was purified by silica gel chromatography (25% EtOAc/Hexanes) to yield a brown oil (1.94 g, 45% yield). HR-EI MS (M).sup.+ m/z calcd 260.07, found 260.0715.
13. Synthesis of 2-(chloromethyl)-3-(2-chlorophenyl)-5-methylquinazolin-4(3H)-one
[0137]Chloroacetylchloride (0.72 mL, 9 mmol) was added to a solution of 2-amino-N-(2-chlorophenyl)-6-methylbenzamide (0.8 g, 3.06 mmol) in acetic acid (10 mL) and the reaction heated to reflux. After 2.5 hours the reaction was cooled to RT, and concentrated in vacuo. The product was purified by silica gel chromatography (10% EtOAc/Hexanes) to yield a white solid (0.353 g, 36% yield). HR-EI MS (M).sup.+ m/z calcd 318.0327, found 318.0321.
14. Synthesis of 2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chloroph- enyl)-5-methylquinazolin-4(3H)-one
[0138]2-(chloromethyl)-3-(2-chlorophenyl)-5-methylquinazolin-4(3H)-one (0.112 g, 0.35 mmol) and 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (0.138 g, 0.053 mmol) were added to DMF (5 mL) and K2CO3 (0.096 g, 0.7 mmol) and allowed to stir at RT in the dark for 72 hours. The product was precipitated by addition of water (50 mL) and collected by filtration. The precipitate was further purified by RP-HPLC (MeCN:H2O:0.1% TFA).
15. Synthesis of S1
[0139]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chl- orophenyl)-5-methylquinazolin-4(3H)-one (60 mg, 0.11 mmol), m-phenol boronic acid (17 mg, 0.121 mmol) and tetrakis(triphenylphosphine)palladium (25 mg, 0.022 mmol) were dissolved in a solution of DME (10 mL), EtOH (1.6 mL) and saturated aqueous Na2CO3 (2.75 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. The organic extract was concentrated in vacuo and purified by RP-HPLC (MeCN:H2O:0.1% TFA). LR-ESI MS (M+H).sup.+ m/z calcd 510.1, found 510.0.
16. Synthesis of S34
[0140]2-((4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl- -3-O-- tolylquinazolin-4(3H)-one (50 mg, 0.096 mmol), benzene 3-sulphonamide boronic ester (29.7 mg, 0.105 mmol) and tetrakis(triphenylphosphine)palladium (22 mg, 0.019 mmol) were dissolved in a solution of DME (10 mL), EtOH (1.6 mL) and saturated aqueous Na2CO3 (2.75 mL). The reaction was heated to reflux overnight under an argon atmosphere. The following day the reaction was poured into water, and the aqueous phase extracted three times with CH2Cl2. LR-ESI MS (M+H).sup.+ m/z calcd 553.2, found 553.0.
[0141]C. PI3-Kinase-Structural Studies
[0142]Crystal structures of p110γ have been reported, alone and in complex with ATP or pan-specific inhibitors such as LY294002 and wortmannin (Walker et al., 2000; Walker et al., 1999). To explore how potent and selective inhibitors bind, the crystal structures of PI3-K inhibitors from three chemotypes bound to human p110γ were determined at 2.5-2.6 Å resolution: the quinazoline purine PIK-39, the imidazopyridine PIK-90 and the phenylthiazole PIK-93 (FIG. 2).
[0143]Based on these co-crystal structures and a conserved arylmorpholine pharmacophore model, structural models were generated for three additional chemotypes bound to p110γ: the pyridinylfuranopyrimidine PI-103, the morpholinochromone PIK-108, and the morpholinopyranone KU-55933 (FIG. 2). Model-building for these inhibitors was guided by the observation that each compound contains the key arylmorpholine pharmacophore found in LY294002.
[0144]PIK-39 is an isoquinoline purine that inhibits p110 δ at mid-nanomolar concentrations, p110γ and p110β at concentrations ˜100-fold higher, and shows no activity against any other PI3-K family member, including p110α, at concentrations up to 100 μM (FIG. 5). The biochemical selectivity of this compound is achieved through an unusual binding mode revealed in its co-crystal structure with p110γ (FIG. 2C). Only the mercaptopurine moiety of PIK-39 makes contacts within the interior of the ATP binding pocket, and this ring system is rotated ˜110° and twisted ˜35° out of the plane relative to the adenine of the ATP. In this orientation, it satisfies hydrogen bonds to the backbone amides of Val 882 and Glu 880 (thereby recapitulating the hydrogen bonds made by N1 and N6 of adenine).
[0145]In contrast to other PI3-K inhibitor structures, PIK-39 does not access the deeper pocket in the active site interior (FIG. 2C, lightly shaded area labeled as "Affinity Pocket"). Instead, the aryl-isoquinoline moiety of PIK-39 extends out to the entrance of the ATP binding pocket (FIG. 2B). In this region, the kinase accommodates the inhibitor by undergoing a conformational rearrangement in which Met 804 shifts from an "up" position, in which it forms the ceiling of the ATP binding pocket, to a "down" position which it packs against the isoquinoline moiety. The effect of this movement, which is unique to the PIK-39 structure (FIG. 2B), is to create a novel hydrophobic pocket between Met 804 and Trp812 at the entrance to the ATP binding site. This induced-fit pocket buries ˜180 Å2 of solvent accessible inhibitor surface area, enabling PIK-39 to achieve nanomolar affinity despite limited contacts within the active site core.
[0146]Co-crystal structures of PIK-90 and PIK-93 compounds bound to p110γ were determined. PIK-90 and PIK-93 both make a hydrogen bond to the backbone amide nitrogen of Val 882 (FIG. 2D), an interaction conserved among all known PI3-K inhibitors (Walker et al., 2000). In addition to this hydrogen bond, PIK-93 makes a second hydrogen bond to the backbone carbonyl of Val 882 and a third between its sulphonamide moiety and the side chain of Asp964. PIK-93 is one of the most polar inhibitors in our panel (clogP=1.69) and these extended polar interactions may compensate for its limited hydrophobic surface area.
[0147]PIK-90 binds in a mode similar to PIK-93, although this larger compound makes more extensive hydrophobic interactions, burying 327 Å2 of solvent accessible surface area. To achieve this, PIK-90 projects its pyridine ring into a deeper cavity that is partially accessed by PIK-93 but not occupied by ATP (FIG. 2D, lightly shaded circle). In this region, the pyridine ring of PIK-90 is poised to make a hydrogen bond to Lys 833, and we find that replacement of this pyridine nitrogen with carbon results in a 100-fold loss in affinity (PIK-95, FIG. 4). PI-103, a third multi-targeted PI3K inhibitor, projects a phenol into the same pocket based on an arylmorpholine pharmacophore model (FIG. 2D).
[0148]Two structural features distinguish these potent, multi-targeted inhibitors from the more selective compounds in our panel. First, these compounds adopt a flat conformation in the ATP binding pocket, whereas highly selective inhibitors project out of the plane occupied by ATP (FIG. 2). Second, the most potent inhibitors project into a deeper binding pocket that is not accessed by ATP (FIG. 2A). Much of the surface of this affinity pocket is contributed by the side-chain of Ile 879.
[0149]The mercaptopurine in the PIK-39 structure was replaced with adenine to yield a model of IC87114 (FIG. 3A). This substitution provided the adenine of IC87114 in the correct orientation to make the same hydrogen bonds as the mercaptopurine of PIK-39, even though these two ring systems are rotated by 110° with respect to each other.
[0150]Unlike other inhibitor chemotypes, PIK-39 does not exploit the PI3-kinase affinity pocket (FIG. 2C). The pyrazolopyrimidine analog of IC87114 (PIK-293) as well as a novel analog containing an m-phenol (PIK-294, FIG. 3A) were then tested for inhibition of the class I PI3-Ks. PIK-294 was up to 60-fold more potent than PIK-293 (FIG. 3A).
[0151]The structure of PIK-39 bound to p110γ reveals a conformational rearrangement of Met 804 that creates an induced pocket, and we have hypothesized that this conformational rearrangement underlies the selectivity of PIK-39 for p110 δ. A prediction of this model is that mutation of Met 804 should perturb the binding of p110 δ-selective inhibitors (which access the induced pocket), but not affect other classes of inhibitors (which do not access this pocket). Modeling suggests that mutation of Met 804 to a β-branched amino acid (such as valine or isoleucine) should restrict the pocket formed by rearrangement of that residue (FIG. 3B, right). Therefore, we mutated the corresponding residue in p110 δ(Met 752) to valine or isoleucine, expressed and purified these kinases, and tested them for sensitivity to PI3-K inhibitors (FIG. 3B). We find that M7521 and M752V p110 δ are resistant to the p110 δ-selective inhibitors PIK-39 and IC87114, but retain sensitivity to the p110α/multi-targeted inhibitors PIK-90, PIK-93, and PI-103. This chemotype-specific resistance supports the unique role of Met 752 in gating an inducible selectivity pocket.
[0152]Antagonist modeling was performed using the PyMOL Molecular Graphics System. All p110γ crystal structures (PDB codes in parentheses), including the Apo (1E8Y), ATP (1E8X), Wortmannin (1E7U), LY294002 (1E7V), Quercetin (1E8W), Myricetin (1E90), and Staurosporine (1E8Z), PIK-90, PIK-93, and PIK-39 bound forms were structurally aligned using PyMOL's align function. Models for the inhibitors PIK-108, KU-55933, and PI-103 were built on top of the LY294002 arylmorpholine scaffold (1E7V) using PyMOL's fragment building function. A model for the inhibitor IC87114 was similarly built on top of the PIK-39 aryl-isoquinoline scaffold.
[0153]The model for PI-103 was built into the protein structure of p110γ bound to PIK-90, because the PIK-90 structure contains the enlarged affinity pocket that is necessary to accommodate PIK-103's phenolic moiety (the PIK-90 p110γ structure otherwise does not exhibit any conformational differences in the arymorpholine-binding region in comparison to the LY294002-bound p110γ structure). The models for PIK-108, KU-55933, and IC87114 were built into the protein structure of p110γ bound to PIK-39 because these inhibitors possess bulky groups that project out of the adenine plane and are likely to exploit the unique "Met 804 down" induced-fit pocket. In all inhibitor models, the choice of protein structure and inhibitor binding mode is based on extensive biochemical SAR as well as inhibitor geometry. The protein structures and inhibitor models have not been minimized to optimize binding energy, but care was taken to prevent any gross steric clashes and to satisfy key hydrogen bonds.
[0154]D. Expression and Assays of p110α/p85α, p110β/p85α, p110β/p85α, and p110γ
[0155]The class I PI3-Ks were either purchased (p110α/p85α, p110β/p85α, p110 δ/p85α from Upstate, and p110γ from Sigma) or expressed as previously described (Knight et al., 2004). IC50 values were measured using either a standard TLC assay for lipid kinase activity (described below) or a high-throughput membrane capture assay. Kinase reactions were performed by preparing a reaction mixture containing kinase, inhibitor (2% DMSO final concentration), buffer (25 mM HEPES, pH 7.4, 10 mM MgCl2), and freshly sonicated phosphatidylinositol (100 μg/ml). Reactions were initiated by the addition of ATP containing 10 μCi of γ-32P-ATP to a final concentration 10 or 100 μM, as indicated in FIG. 5, and allowed to proceed for 5 minutes at room temperature. For TLC analysis, reactions were then terminated by the addition of 105 μl 1N HCl followed by 160 μl CHCl3:MeOH (1:1). The biphasic mixture was vortexed, briefly centrifuged, and the organic phase transferred to a new tube using a gel loading pipette tip precoated with CHCl3. This extract was spotted on TLC plates and developed for 3-4 hours in a 65:35 solution of n-propanol:1M acetic acid. The TLC plates were then dried, exposed to a phosphorimager screen (Storm, Amersham), and quantitated. For each compound, kinase activity was measured at 10-12 inhibitor concentrations representing two-fold dilutions from the highest concentration tested (typically, 200 μM). For compounds showing significant activity, IC50 determinations were repeated two to four times, and the reported value is the average of these independent measurements.
[0156]Results are set forth in Table 1 below.
TABLE-US-00001 TABLE 1 Compound IC50 MW Structure p110α p110β p110γ p110δ S1 (509.9464) ##STR00005## + ++ +++ +++ S2 (523.33) ##STR00006## ++ ++ +++ +++ S3 (489.53) ##STR00007## + +++ +++ +++ S4 (557.63) ##STR00008## + + ++ +++ S5 (521.59) ##STR00009## + ++ +++ +++ S6 (533.58) ##STR00010## + ++ +++ +++ S7 (565.62) ##STR00011## + ++ ++ +++ S8 (579.65) ##STR00012## ++ ++ ++ +++ S9 (507.52) ##STR00013## ++ +++ +++ +++ S10 (507.52) ##STR00014## ++ +++ +++ +++ S11 (503.55) ##STR00015## ++ ++ +++ +++ S12 (523.97) ##STR00016## ++ ++ +++ +++ S13 (507.52) ##STR00017## ++ ++ +++ +++ S14 (512.56) ##STR00018## + ++ +++ +++ S15 (512.56) ##STR00019## + ++ ++ +++ S16 (521.55) ##STR00020## + ++ ++ +++ S17 (521.55) ##STR00021## ++ ++ +++ +++ S18 (608.52) ##STR00022## + + + ++ S19 (461.52) ##STR00023## + ++ ++ +++ S20 (513.55) ##STR00024## ++ ++ +++ +++ S21 (512.56) ##STR00025## + ++ ++ +++ S22 (498.54) ##STR00026## + ++ ++ +++ S23 (498.54) ##STR00027## + ++ +++ +++ S24 (524.58) ##STR00028## ++ ++ +++ +++ S25 (451.48) ##STR00029## ++ +++ ++ +++ S26 (464.52) ##STR00030## +++ S27 (478.55) ##STR00031## ++ S28 (465.51) ##STR00032## + ++ ++ +++ S29 (465.51) ##STR00033## ++ +++ +++ +++ S30 (493.52) ##STR00034## ++ + ++ +++ S31 (488.54) ##STR00035## +++ S32 ##STR00036## S33 ##STR00037## S34 ##STR00038## The symbol +++ represents an IC50 of less than 1 μM; the symbol ++ represents an IC50 value from 1 μM to 100 μM; and + represents an IC50 value of more than 100 μM.
IX. References
[0157]Alaimo, P. J., Knight, Z. A., and Shokat, K. M. (2005). Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg Med Chem 13, 2825-2836. [0158]Asano, T., Kanda, A., Katagiri, H., Nawano, M., Ogihara, T., Inukai, K., Anai, M., Fukushima, Y., Yazaki, Y., Kikuchi, M., et al. (2000). p110beta is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J Biol Chem 275, 17671-17676. [0159]Bi, L., Okabe, I., Bernard, D. J., and Nussbaum, R. L. (2002). Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13, 169-172. [0160]Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., and Nussbaum, R. L. (1999). Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274, 10963-10968. [0161]Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., and Cantley, L. C. (2005). Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 25, 1596-1607. [0162]Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B., et al. (2005). Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. [0163]Cantley, L. C., and Neel, B. G. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96, 4240-4245. [0164]Condliffe, A. M., Davidson, K., Anderson, K. E., Ellson, C. D., Crabbe, T., Okkenhaug, K., Vanhaesebroeck, B., Turner, M., Webb, L., Wymann, M. P., et al. (2005). Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432-1440. [0165]Domin, J., and Waterfield, M. D. (1997). Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett 410, 91-95. [0166]Feng, J., Park, J., Cron, P., Hess, D., and Hemmings, B. A. (2004). Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279, 41189-41196. [0167]Fruman, D. A., Meyers, R. E., and Cantley, L. C. (1998). Phosphoinositide kinases. Annu Rev Biochem 67, 481-507. [0168]Harrington, L. S., Findlay, G. M., and Lamb, R. F. (2005). Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30, 35-42. [0169]Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., and Smith, G. C. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64, 9152-9159. [0170]Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005). PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11, 507-514. [0171]Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17, 615-675. [0172]Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C. B., Coan, K., Abraham, R. T., and Shokat, K. M. (2004). Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12, 4749-4759. [0173]Knight, Z. A., and Shokat, K. M. (2005). Features of selective kinase inhibitors. Chem Biol 12, 621-637.
[0174]Lau, A., Swinbank, K. M., Ahmed, P. S., Taylor, D. L., Jackson, S. P., Smith, G. C., and O'Connor, M. J. (2005). Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 7, 493-500. [0175]Luo, J., Field, S. J., Lee, J. Y., Engelman, J. A., and Cantley, L. C. (2005). The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170, 455-464. [0176]Madhusudan, Trafny, E. A., Xuong, N. H., Adams, J. A., Teneyck, L. F., Taylor, S. S., and Sowadski, J. M. (1994). cAMP-Dependent Protein-Kinase--Crystallographic Insights Into Substrate Recognition and Phosphotransfer. Protein Science 3, 176-187. [0177]Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S. D., et al. (2004). PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375-387. [0178]Peng, Y., Woods, R. G., Beamish, H., Ye, R., Lees-Miller, S. P., Lavin, M. F., and Bedford, J. S. (2005). Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM. Cancer Res 65, 1670-1677. [0179]Ruderman, N. B., Kapeller, R., White, M. F., and Cantley, L. C. (1990). Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci USA 87, 1411-1415. [0180]Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., and Staunton, D. E. (2003). Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 170, 2647-2654.
[0181]Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. [0182]Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942. [0183]Schindler, T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A., and Kuriyan, J. (1999). Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 3, 639-648. [0184]Schmid, A. C., Byrne, R. D., Vilar, R., and Woscholski, R. (2004). Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett 566, 35-38. [0185]Ueki, K., Fruman, D. A., Yballe, C. M., Fasshauer, M., Klein, J., Asano, T., Cantley, L. C., and Kahn, C. R. (2003). Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem 278, 48453-48466. [0186]Ueki, K., Yballe, C. M., Brachmann, S. M., Vicent, D., Watt, J. M., Kahn, C. R., and Cantley, L. C. (2002). Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99, 419-424. [0187]Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., and Foukas, L. C. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30, 194-204. [0188]Viniegra, J. G., Martinez, N., Modirassari, P., Losa, J. H., Parada Cobo, C., Lobo, V. J., Luquero, C. I., Alvarez-Vallina, L., Ramon y Cajal, S., Rojas, J. M., and Sanchez-Prieto, R. (2005). Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 280, 4029-4036. [0189]Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., and Williams, R. L. (2000). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6, 909-919. [0190]Walker, E. H., Perisic, O., Ried, C., Stephens, L., and Williams, R. L. (1999). Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313-320. [0191]Ward, S., Sotsios, Y., Dowden, J., Bruce, I., and Finan, P. (2003). Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 10, 207-213. [0192]Yart, A., Roche, S., Wetzker, R., Laffargue, M., Tonks, N., Mayeux, P., Chap, H., and Raynal, P. (2002). A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem 277, 21167-21178. [0193]Yu, J., Zhang, Y., Mcllroy, J., Rordorf-Nikolic, T., Orr, G. A., and Backer, J. M. (1998). Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18, 1379-1387. [0194]Almirante, L., Mugnaini, A., De Toma, N., Gamba, A., and Murmann, W. (1970). Imidazole Derivatives. IV. Synthesis and Pharmacological Activity of Oxygenated Derivatives of Imidazo[1,2-a]pyridine. Journal of Medicinal Chemistry 13, 1048-1051. [0195]Armstrong, V. W., N.H., C., and Ramage, R. (1975). A new brominating reagent: 2-carboxyethyltriphenylphosphonium perbromide. Tetrahedron Letters 6, 373-376. [0196]Bateman, A., Birney, E., Durbin, R., Eddy, S. R., Howe, K. L., and Sonnhammer, E. L. (2000). The Pfam protein families database. Nucleic Acids Res 28, 263-266. [0197]Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A., and Hall, M. N. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128. [0198]Jolliffe, I. T. (2002). Principal component analysis, 2nd edn (New York: Springer). [0199]Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C. B., Coan, K., Abraham, R. T., and Shokat, K. M. (2004). Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12, 4749-4759. [0200]Lakshmanan, J., Elmendorf, J. S., and Ozcan, S. (2003). Analysis of insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes. Methods Mol Med 83, 97-103. [0201]Lombardino, J. G. (1965). Preparation and new reactions of imidazo[1,2-a]pyridines. Journal of Organic Chemistry 30, 2403-2407. [0202]Mathworks (2004). Statistics Toolbox: For use with MATLAB. User's Guide, Version 5. Chapter 7: Principal Component Analysis: Mathworks). [0203]Mhaske, S. B., and Argade, N. P. (2004). Regioselective quinazolinone-directed ortho lithiation of quinazolinoylquinoline: practical synthesis of naturally occurring human DNA topoisomerase I poison luotonin a and luotonins B and E. J Org Chem 69, 4563-4566. [0204]Morris, J., Wishka, D. G., and Fang, Y. (1994). A cyclodehydration route to 2-aminochromones. Synthetic Communications 24, 849-858. [0205]Serunian, L. A., Auger, K. R., and Cantley, L. C. (1991). Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. Methods Enzymol 198, 78-87.
Sequence CWU
1
411044PRTHomo sapiens 1Met Pro Pro Gly Val Asp Cys Pro Met Glu Phe Trp Thr
Lys Glu Glu1 5 10 15Asn
Gln Ser Val Val Val Asp Phe Leu Leu Pro Thr Gly Val Tyr Leu 20
25 30Asn Phe Pro Val Ser Arg Asn Ala
Asn Leu Ser Thr Ile Lys Gln Leu 35 40
45Leu Trp His Arg Ala Gln Tyr Glu Pro Leu Phe His Met Leu Ser Gly
50 55 60Pro Glu Ala Tyr Val Phe Thr Cys
Ile Asn Gln Thr Ala Glu Gln Gln65 70 75
80Glu Leu Glu Asp Glu Gln Arg Arg Leu Cys Asp Val Gln
Pro Phe Leu 85 90 95Pro
Val Leu Arg Leu Val Ala Arg Glu Gly Asp Arg Val Lys Lys Leu
100 105 110Ile Asn Ser Gln Ile Ser Leu
Leu Ile Gly Lys Gly Leu His Glu Phe 115 120
125Asp Ser Leu Cys Asp Pro Glu Val Asn Asp Phe Arg Ala Lys Met
Cys 130 135 140Gln Phe Cys Glu Glu Ala
Ala Ala Arg Arg Gln Gln Leu Gly Trp Glu145 150
155 160Ala Trp Leu Gln Tyr Ser Phe Pro Leu Gln Leu
Glu Pro Ser Ala Gln 165 170
175Thr Trp Gly Pro Gly Thr Leu Arg Leu Pro Asn Arg Ala Leu Leu Val
180 185 190Asn Val Lys Phe Glu Gly
Ser Glu Glu Ser Phe Thr Phe Gln Val Ser 195 200
205Thr Lys Asp Val Pro Leu Ala Leu Met Ala Cys Ala Leu Arg
Lys Lys 210 215 220Ala Thr Val Phe Arg
Gln Pro Leu Val Glu Gln Pro Glu Asp Tyr Thr225 230
235 240Leu Gln Val Asn Gly Arg His Glu Tyr Leu
Tyr Gly Asn Tyr Pro Leu 245 250
255Cys Gln Phe Gln Tyr Ile Cys Ser Cys Leu His Ser Gly Leu Thr Pro
260 265 270His Leu Thr Met Val
His Ser Ser Ser Ile Leu Ala Met Arg Asp Glu 275
280 285Gln Ser Asn Pro Ala Pro Gln Val Gln Lys Pro Arg
Ala Lys Pro Pro 290 295 300Pro Ile Pro
Ala Lys Lys Pro Ser Ser Val Ser Leu Trp Ser Leu Glu305
310 315 320Gln Pro Phe Arg Ile Glu Leu
Ile Gln Gly Ser Lys Val Asn Ala Asp 325
330 335Glu Arg Met Lys Leu Val Val Gln Ala Gly Leu Phe
His Gly Asn Glu 340 345 350Met
Leu Cys Lys Thr Val Ser Ser Ser Glu Val Ser Val Cys Ser Glu 355
360 365Pro Val Trp Lys Gln Arg Leu Glu Phe
Asp Ile Asn Ile Cys Asp Leu 370 375
380Pro Arg Met Ala Arg Leu Cys Phe Ala Leu Tyr Ala Val Ile Glu Lys385
390 395 400Ala Lys Lys Ala
Arg Ser Thr Lys Lys Lys Ser Lys Lys Ala Asp Cys 405
410 415Pro Ile Ala Trp Ala Asn Leu Met Leu Phe
Asp Tyr Lys Asp Gln Leu 420 425
430Lys Thr Gly Glu Arg Cys Leu Tyr Met Trp Pro Ser Val Pro Asp Glu
435 440 445Lys Gly Glu Leu Leu Asn Pro
Thr Gly Thr Val Arg Ser Asn Pro Asn 450 455
460Thr Asp Ser Ala Ala Ala Leu Leu Ile Cys Leu Pro Glu Val Ala
Pro465 470 475 480His Pro
Val Tyr Tyr Pro Ala Leu Glu Lys Ile Leu Glu Leu Gly Arg
485 490 495His Ser Glu Cys Val His Val
Thr Glu Glu Glu Gln Leu Gln Leu Arg 500 505
510Glu Ile Leu Glu Arg Arg Gly Ser Gly Glu Leu Tyr Glu His
Glu Lys 515 520 525Asp Leu Val Trp
Lys Leu Arg His Glu Val Gln Glu His Phe Pro Glu 530
535 540Ala Leu Ala Arg Leu Leu Leu Val Thr Lys Trp Asn
Lys His Glu Asp545 550 555
560Val Ala Gln Met Leu Tyr Leu Leu Cys Ser Trp Pro Glu Leu Pro Val
565 570 575Leu Ser Ala Leu Glu
Leu Leu Asp Phe Ser Phe Pro Asp Cys His Val 580
585 590Gly Ser Phe Ala Ile Lys Ser Leu Arg Lys Leu Thr
Asp Asp Glu Leu 595 600 605Phe Gln
Tyr Leu Leu Gln Leu Val Gln Val Leu Lys Tyr Glu Ser Tyr 610
615 620Leu Asp Cys Glu Leu Thr Lys Phe Leu Leu Asp
Arg Ala Leu Ala Asn625 630 635
640Arg Lys Ile Gly His Phe Leu Phe Trp His Leu Arg Ser Glu Met His
645 650 655Val Pro Ser Val
Ala Leu Arg Phe Gly Leu Ile Leu Glu Ala Tyr Cys 660
665 670Arg Gly Ser Thr His His Met Lys Val Leu Met
Lys Gln Gly Glu Ala 675 680 685Leu
Ser Lys Leu Lys Ala Leu Asn Asp Phe Val Lys Leu Ser Ser Gln 690
695 700Lys Thr Pro Lys Pro Gln Thr Lys Glu Leu
Met His Leu Cys Met Arg705 710 715
720Gln Glu Ala Tyr Leu Glu Ala Leu Ser His Leu Gln Ser Pro Leu
Asp 725 730 735Pro Ser Thr
Leu Leu Ala Glu Val Cys Val Glu Gln Cys Thr Phe Met 740
745 750Asp Ser Lys Met Lys Pro Leu Trp Ile Met
Tyr Ser Asn Glu Glu Ala 755 760
765Gly Ser Gly Gly Ser Val Gly Ile Ile Phe Lys Asn Gly Asp Asp Leu 770
775 780Arg Gln Asp Met Leu Thr Leu Gln
Met Ile Gln Leu Met Asp Val Leu785 790
795 800Trp Lys Gln Glu Gly Leu Asp Leu Arg Met Thr Pro
Tyr Gly Cys Leu 805 810
815Pro Thr Gly Asp Arg Thr Gly Leu Ile Glu Val Val Leu Arg Ser Asp
820 825 830Thr Ile Ala Asn Ile Gln
Leu Asn Lys Ser Asn Met Ala Ala Thr Ala 835 840
845Ala Phe Asn Lys Asp Ala Leu Leu Asn Trp Leu Lys Ser Lys
Asn Pro 850 855 860Gly Glu Ala Leu Asp
Arg Ala Ile Glu Glu Phe Thr Leu Ser Cys Ala865 870
875 880Gly Tyr Cys Val Ala Thr Tyr Val Leu Gly
Ile Gly Asp Arg His Ser 885 890
895Asp Asn Ile Met Ile Arg Glu Ser Gly Gln Leu Phe His Ile Asp Phe
900 905 910Gly His Phe Leu Gly
Asn Phe Lys Thr Lys Phe Gly Ile Asn Arg Glu 915
920 925Arg Val Pro Phe Ile Leu Thr Tyr Asp Phe Val His
Val Ile Gln Gln 930 935 940Gly Lys Thr
Asn Asn Ser Glu Lys Phe Glu Arg Phe Arg Gly Tyr Cys945
950 955 960Glu Arg Ala Tyr Thr Ile Leu
Arg Arg His Gly Leu Leu Phe Leu His 965
970 975Leu Phe Ala Leu Met Arg Ala Ala Gly Leu Pro Glu
Leu Ser Cys Ser 980 985 990Lys
Asp Ile Gln Tyr Leu Lys Asp Ser Leu Ala Leu Gly Lys Thr Glu 995
1000 1005Glu Glu Ala Leu Lys His Phe Arg Val
Lys Phe Asn Glu Ala Leu Arg 1010 1015
1020Glu Ser Trp Lys Thr Lys Val Asn Trp Leu Ala His Asn Val Ser Lys1025
1030 1035 1040Asp Asn Arg
Gln21102PRTHomo sapiens 2Met Glu Leu Glu Asn Tyr Lys Gln Pro Val Val Leu
Arg Glu Asp Asn1 5 10
15Cys Arg Arg Arg Arg Arg Met Lys Pro Arg Ser Ala Ala Ala Ser Leu
20 25 30Ser Ser Met Glu Leu Ile Pro
Ile Glu Phe Val Leu Pro Thr Ser Gln 35 40
45Arg Lys Cys Lys Ser Pro Glu Thr Ala Leu Leu His Val Ala Gly
His 50 55 60Gly Asn Val Glu Gln Met
Lys Ala Gln Val Trp Leu Arg Ala Leu Glu65 70
75 80Thr Ser Val Ala Ala Asp Phe Tyr His Arg Leu
Gly Pro His His Phe 85 90
95Leu Leu Leu Tyr Gln Lys Lys Gly Gln Trp Tyr Glu Ile Tyr Asp Lys
100 105 110Tyr Gln Val Val Gln Thr
Leu Asp Cys Leu Arg Tyr Trp Lys Ala Thr 115 120
125His Arg Ser Pro Gly Gln Ile His Leu Val Gln Arg His Pro
Pro Ser 130 135 140Glu Glu Ser Gln Ala
Phe Gln Arg Gln Leu Thr Ala Leu Ile Gly Tyr145 150
155 160Asp Val Thr Asp Val Ser Asn Val His Asp
Asp Glu Leu Glu Phe Thr 165 170
175Arg Arg Gly Leu Val Thr Pro Arg Met Ala Glu Val Ala Ser Arg Asp
180 185 190Pro Lys Leu Tyr Ala
Met His Pro Trp Val Thr Ser Lys Pro Leu Pro 195
200 205Glu Tyr Leu Trp Lys Lys Ile Ala Asn Asn Cys Ile
Phe Ile Val Ile 210 215 220His Arg Ser
Thr Thr Ser Gln Thr Ile Lys Val Ser Pro Asp Asp Thr225
230 235 240Pro Gly Ala Ile Leu Gln Ser
Phe Phe Thr Lys Met Ala Lys Lys Lys 245
250 255Ser Leu Met Asp Ile Pro Glu Ser Gln Ser Glu Gln
Asp Phe Val Leu 260 265 270Arg
Val Cys Gly Arg Asp Glu Tyr Leu Val Gly Glu Thr Pro Ile Lys 275
280 285Asn Phe Gln Trp Val Arg His Cys Leu
Lys Asn Gly Glu Glu Ile His 290 295
300Val Val Leu Asp Thr Pro Pro Asp Pro Ala Leu Asp Glu Val Arg Lys305
310 315 320Glu Glu Trp Pro
Leu Val Asp Asp Cys Thr Gly Val Thr Gly Tyr His 325
330 335Glu Gln Leu Thr Ile His Gly Lys Asp His
Glu Ser Val Phe Thr Val 340 345
350Ser Leu Trp Asp Cys Asp Arg Lys Phe Arg Val Lys Ile Arg Gly Ile
355 360 365Asp Ile Pro Val Leu Pro Arg
Asn Thr Asp Leu Thr Val Phe Val Glu 370 375
380Ala Asn Ile Gln His Gly Gln Gln Val Leu Cys Gln Arg Arg Thr
Ser385 390 395 400Pro Lys
Pro Phe Thr Glu Glu Val Leu Trp Asn Val Trp Leu Glu Phe
405 410 415Ser Ile Lys Ile Lys Asp Leu
Pro Lys Gly Ala Leu Leu Asn Leu Gln 420 425
430Ile Tyr Cys Gly Lys Ala Pro Ala Leu Ser Ser Lys Ala Ser
Ala Glu 435 440 445Ser Pro Ser Ser
Glu Ser Lys Gly Lys Val Gln Leu Leu Tyr Tyr Val 450
455 460Asn Leu Leu Leu Ile Asp His Arg Phe Leu Leu Arg
Arg Gly Glu Tyr465 470 475
480Val Leu His Met Trp Gln Ile Ser Gly Lys Gly Glu Asp Gln Gly Ser
485 490 495Phe Asn Ala Asp Lys
Leu Thr Ser Ala Thr Asn Pro Asp Lys Glu Asn 500
505 510Ser Met Ser Ile Ser Ile Leu Leu Asp Asn Tyr Cys
His Pro Ile Ala 515 520 525Leu Pro
Lys His Gln Pro Thr Pro Asp Pro Glu Gly Asp Arg Val Arg 530
535 540Ala Glu Met Pro Asn Gln Leu Arg Lys Gln Leu
Glu Ala Ile Ile Ala545 550 555
560Thr Asp Pro Leu Asn Pro Leu Thr Ala Glu Asp Lys Glu Leu Leu Trp
565 570 575His Phe Arg Tyr
Glu Ser Leu Lys His Pro Lys Ala Tyr Pro Lys Leu 580
585 590Phe Ser Ser Val Lys Trp Gly Gln Gln Glu Ile
Val Ala Lys Thr Tyr 595 600 605Gln
Leu Leu Ala Arg Arg Glu Val Trp Asp Gln Ser Ala Leu Asp Val 610
615 620Gly Leu Thr Met Gln Leu Leu Asp Cys Asn
Phe Ser Asp Glu Asn Val625 630 635
640Arg Ala Ile Ala Val Gln Lys Leu Glu Ser Leu Glu Asp Asp Asp
Val 645 650 655Leu His Tyr
Leu Leu Gln Leu Val Gln Ala Val Lys Phe Glu Pro Tyr 660
665 670His Asp Ser Ala Leu Ala Arg Phe Leu Leu
Lys Arg Gly Leu Arg Asn 675 680
685Lys Arg Ile Gly His Phe Leu Phe Trp Phe Leu Arg Ser Glu Ile Ala 690
695 700Gln Ser Arg His Tyr Gln Gln Arg
Phe Ala Val Ile Leu Glu Ala Tyr705 710
715 720Leu Arg Gly Cys Gly Thr Ala Met Leu His Asp Phe
Thr Gln Gln Val 725 730
735Gln Val Ile Glu Met Leu Gln Lys Val Thr Leu Asp Ile Lys Ser Leu
740 745 750Ser Ala Glu Lys Tyr Asp
Val Ser Ser Gln Val Ile Ser Gln Leu Lys 755 760
765Gln Lys Leu Glu Asn Leu Gln Asn Ser Gln Leu Pro Glu Ser
Phe Arg 770 775 780Val Pro Tyr Asp Pro
Gly Leu Lys Ala Gly Ala Leu Ala Ile Glu Lys785 790
795 800Cys Lys Val Met Ala Ser Lys Lys Lys Pro
Leu Trp Leu Glu Phe Lys 805 810
815Cys Ala Asp Pro Thr Ala Leu Ser Asn Glu Thr Ile Gly Ile Ile Phe
820 825 830Lys His Gly Asp Asp
Leu Arg Gln Asp Met Leu Ile Leu Gln Ile Leu 835
840 845Arg Ile Met Glu Ser Ile Trp Glu Thr Glu Ser Leu
Asp Leu Cys Leu 850 855 860Leu Pro Tyr
Gly Cys Ile Ser Thr Gly Asp Lys Ile Gly Met Ile Glu865
870 875 880Ile Val Lys Asp Ala Thr Thr
Ile Ala Lys Ile Gln Gln Ser Thr Val 885
890 895Gly Asn Thr Gly Ala Phe Lys Asp Glu Val Leu Asn
His Trp Leu Lys 900 905 910Glu
Lys Ser Pro Thr Glu Glu Lys Phe Gln Ala Ala Val Glu Arg Phe 915
920 925Val Tyr Ser Cys Ala Gly Tyr Cys Val
Ala Thr Phe Val Leu Gly Ile 930 935
940Gly Asp Arg His Asn Asp Asn Ile Met Ile Thr Glu Thr Gly Asn Leu945
950 955 960Phe His Ile Asp
Phe Gly His Ile Leu Gly Asn Tyr Lys Ser Phe Leu 965
970 975Gly Ile Asn Lys Glu Arg Val Pro Phe Val
Leu Thr Pro Asp Phe Leu 980 985
990Phe Val Met Gly Thr Ser Gly Lys Lys Thr Ser Pro His Phe Gln Lys
995 1000 1005Phe Gln Asp Ile Cys Val Lys
Ala Tyr Leu Ala Leu Arg His His Thr 1010 1015
1020Asn Leu Leu Ile Ile Leu Phe Ser Met Met Leu Met Thr Gly Met
Pro1025 1030 1035 1040Gln Leu
Thr Ser Lys Glu Asp Ile Glu Tyr Ile Arg Asp Ala Leu Thr
1045 1050 1055Val Gly Lys Asn Glu Glu Asp
Ala Lys Lys Tyr Phe Leu Asp Gln Ile 1060 1065
1070Glu Val Cys Arg Asp Lys Gly Trp Thr Val Gln Phe Asn Trp
Phe Leu 1075 1080 1085His Leu Val
Leu Gly Ile Lys Gln Gly Glu Lys His Ser Ala 1090 1095
110031068PRTHomo sapiens 3Met Pro Pro Arg Pro Ser Ser Gly
Glu Leu Trp Gly Ile His Leu Met1 5 10
15Pro Pro Arg Ile Leu Val Glu Cys Leu Leu Pro Asn Gly Met
Ile Val 20 25 30Thr Leu Glu
Cys Leu Arg Glu Ala Thr Leu Ile Thr Ile Lys His Glu 35
40 45Leu Phe Lys Glu Ala Arg Lys Tyr Pro Leu His
Gln Leu Leu Gln Asp 50 55 60Glu Ser
Ser Tyr Ile Phe Val Ser Val Thr Gln Glu Ala Glu Arg Glu65
70 75 80Glu Phe Phe Asp Glu Thr Arg
Arg Leu Cys Asp Leu Arg Leu Phe Gln 85 90
95Pro Phe Leu Lys Val Ile Glu Pro Val Gly Asn Arg Glu
Glu Lys Ile 100 105 110Leu Asn
Arg Glu Ile Gly Phe Ala Ile Gly Met Pro Val Cys Glu Phe 115
120 125Asp Met Val Lys Asp Pro Glu Val Gln Asp
Phe Arg Arg Asn Ile Leu 130 135 140Asn
Val Cys Lys Glu Ala Val Asp Leu Arg Asp Leu Asn Ser Pro His145
150 155 160Ser Arg Ala Met Tyr Val
Tyr Pro Pro Asn Val Glu Ser Ser Pro Glu 165
170 175Leu Pro Lys His Ile Tyr Asn Lys Leu Asp Lys Gly
Gln Ile Ile Val 180 185 190Val
Ile Trp Val Ile Val Ser Pro Asn Asn Asp Lys Gln Lys Tyr Thr 195
200 205Leu Lys Ile Asn His Asp Cys Val Pro
Glu Gln Val Ile Ala Glu Ala 210 215
220Ile Arg Lys Lys Thr Arg Ser Met Leu Leu Ser Ser Glu Gln Leu Lys225
230 235 240Leu Cys Val Leu
Glu Tyr Gln Gly Lys Tyr Ile Leu Lys Val Cys Gly 245
250 255Cys Asp Glu Tyr Phe Leu Glu Lys Tyr Pro
Leu Ser Gln Tyr Lys Tyr 260 265
270Ile Arg Ser Cys Ile Met Leu Gly Arg Met Pro Asn Leu Met Leu Met
275 280 285Ala Lys Glu Ser Leu Tyr Ser
Gln Leu Pro Met Asp Cys Phe Thr Met 290 295
300Pro Ser Tyr Ser Arg Arg Ile Ser Thr Ala Thr Pro Tyr Met Asn
Gly305 310 315 320Glu Thr
Ser Thr Lys Ser Leu Trp Val Ile Asn Ser Ala Leu Arg Ile
325 330 335Lys Ile Leu Cys Ala Thr Tyr
Val Asn Val Asn Ile Arg Asp Ile Asp 340 345
350Lys Ile Tyr Val Arg Thr Gly Ile Tyr His Gly Gly Glu Pro
Leu Cys 355 360 365Asp Asn Val Asn
Thr Gln Arg Val Pro Cys Ser Asn Pro Arg Trp Asn 370
375 380Glu Trp Leu Asn Tyr Asp Ile Tyr Ile Pro Asp Leu
Pro Arg Ala Ala385 390 395
400Arg Leu Cys Leu Ser Ile Cys Ser Val Lys Gly Arg Lys Gly Ala Lys
405 410 415Glu Glu His Cys Pro
Leu Ala Trp Gly Asn Ile Asn Leu Phe Asp Tyr 420
425 430Thr Asp Thr Leu Val Ser Gly Lys Met Ala Leu Asn
Leu Trp Pro Val 435 440 445Pro His
Gly Leu Glu Asp Leu Leu Asn Pro Ile Gly Val Thr Gly Ser 450
455 460Asn Pro Asn Lys Glu Thr Pro Cys Leu Glu Leu
Glu Phe Asp Trp Phe465 470 475
480Ser Ser Val Val Lys Phe Pro Asp Met Ser Val Ile Glu Glu His Ala
485 490 495Asn Trp Ser Val
Ser Arg Glu Ala Gly Phe Ser Tyr Ser His Ala Gly 500
505 510Leu Ser Asn Arg Leu Ala Arg Asp Asn Glu Leu
Arg Glu Asn Asp Lys 515 520 525Glu
Gln Leu Lys Ala Ile Ser Thr Arg Asp Pro Leu Ser Glu Ile Thr 530
535 540Glu Gln Glu Lys Asp Phe Leu Trp Ser His
Arg His Tyr Cys Val Thr545 550 555
560Ile Pro Glu Ile Leu Pro Lys Leu Leu Leu Ser Val Lys Trp Asn
Ser 565 570 575Arg Asp Glu
Val Ala Gln Met Tyr Cys Leu Val Lys Asp Trp Pro Pro 580
585 590Ile Lys Pro Glu Gln Ala Met Glu Leu Leu
Asp Cys Asn Tyr Pro Asp 595 600
605Pro Met Val Arg Gly Phe Ala Val Arg Cys Leu Glu Lys Tyr Leu Thr 610
615 620Asp Asp Lys Leu Ser Gln Tyr Leu
Ile Gln Leu Val Gln Val Leu Lys625 630
635 640Tyr Glu Gln Tyr Leu Asp Asn Leu Leu Val Arg Phe
Leu Leu Lys Lys 645 650
655Ala Leu Thr Asn Gln Arg Ile Gly His Phe Phe Phe Trp His Leu Lys
660 665 670Ser Glu Met His Asn Lys
Thr Val Ser Gln Arg Phe Gly Leu Leu Leu 675 680
685Glu Ser Tyr Cys Arg Ala Cys Gly Met Tyr Leu Lys His Leu
Asn Arg 690 695 700Gln Val Glu Ala Met
Glu Lys Leu Ile Asn Leu Thr Asp Ile Leu Lys705 710
715 720Gln Glu Lys Lys Asp Glu Thr Gln Lys Val
Gln Met Lys Phe Leu Val 725 730
735Glu Gln Met Arg Arg Pro Asp Phe Met Asp Ala Leu Gln Gly Phe Leu
740 745 750Ser Pro Leu Asn Pro
Ala His Gln Leu Gly Asn Leu Arg Leu Glu Glu 755
760 765Cys Arg Ile Met Ser Ser Ala Lys Arg Pro Leu Trp
Leu Asn Trp Glu 770 775 780Asn Pro Asp
Ile Met Ser Glu Leu Leu Phe Gln Asn Asn Glu Ile Ile785
790 795 800Phe Lys Asn Gly Asp Asp Leu
Arg Gln Asp Met Leu Thr Leu Gln Ile 805
810 815Ile Arg Ile Met Glu Asn Ile Trp Gln Asn Gln Gly
Leu Asp Leu Arg 820 825 830Met
Leu Pro Tyr Gly Cys Leu Ser Ile Gly Asp Cys Val Gly Leu Ile 835
840 845Glu Val Val Arg Asn Ser His Thr Ile
Met Gln Ile Gln Cys Lys Gly 850 855
860Gly Leu Lys Gly Ala Leu Gln Phe Asn Ser His Thr Leu His Gln Trp865
870 875 880Leu Lys Asp Lys
Asn Lys Gly Glu Ile Tyr Asp Ala Ala Ile Asp Leu 885
890 895Phe Thr Arg Ser Cys Ala Gly Tyr Cys Val
Ala Thr Phe Ile Leu Gly 900 905
910Ile Gly Asp Arg His Asn Ser Asn Ile Met Val Lys Asp Asp Gly Gln
915 920 925Leu Phe His Ile Asp Phe Gly
His Phe Leu Asp His Lys Lys Lys Lys 930 935
940Phe Gly Tyr Lys Arg Glu Arg Val Pro Phe Val Leu Thr Gln Asp
Phe945 950 955 960Leu Ile
Val Ile Ser Lys Gly Ala Gln Glu Cys Thr Lys Thr Arg Glu
965 970 975Phe Glu Arg Phe Gln Glu Met
Cys Tyr Lys Ala Tyr Leu Ala Ile Arg 980 985
990Gln His Ala Asn Leu Phe Ile Asn Leu Phe Ser Met Met Leu
Gly Ser 995 1000 1005Gly Met Pro Glu
Leu Gln Ser Phe Asp Asp Ile Ala Tyr Ile Arg Lys 1010
1015 1020Thr Leu Ala Leu Asp Lys Thr Glu Gln Glu Ala Leu
Glu Tyr Phe Met1025 1030 1035
1040Lys Gln Met Asn Asp Ala His His Gly Gly Trp Thr Thr Lys Met Asp
1045 1050 1055Trp Ile Phe His Thr
Ile Lys Gln His Ala Leu Asn 1060
106541070PRTHomo sapiens 4Met Cys Phe Ser Phe Ile Met Pro Pro Ala Met Ala
Asp Ile Leu Asp1 5 10
15Ile Trp Ala Val Asp Ser Gln Ile Ala Ser Asp Gly Ser Ile Pro Val
20 25 30Asp Phe Leu Leu Pro Thr Gly
Ile Tyr Ile Gln Leu Glu Val Pro Arg 35 40
45Glu Ala Thr Ile Ser Tyr Ile Lys Gln Met Leu Trp Lys Gln Val
His 50 55 60Asn Tyr Pro Met Phe Asn
Leu Leu Met Asp Ile Asp Ser Tyr Met Phe65 70
75 80Ala Cys Val Asn Gln Thr Ala Val Tyr Glu Glu
Leu Glu Asp Glu Thr 85 90
95Arg Arg Leu Cys Asp Val Arg Pro Phe Leu Pro Val Leu Lys Leu Val
100 105 110Thr Arg Ser Cys Asp Pro
Gly Glu Lys Leu Asp Ser Lys Ile Gly Val 115 120
125Leu Ile Gly Lys Gly Leu His Glu Phe Asp Ser Leu Lys Asp
Pro Glu 130 135 140Val Asn Glu Phe Arg
Arg Lys Met Arg Lys Phe Ser Glu Glu Lys Ile145 150
155 160Leu Ser Leu Val Gly Leu Ser Trp Met Asp
Trp Leu Lys Gln Thr Tyr 165 170
175Pro Pro Glu His Glu Pro Ser Ile Pro Glu Asn Leu Glu Asp Lys Leu
180 185 190Tyr Gly Gly Lys Leu
Ile Val Ala Val His Phe Glu Asn Cys Gln Asp 195
200 205Val Phe Ser Phe Gln Val Ser Pro Asn Met Asn Pro
Ile Lys Val Asn 210 215 220Glu Leu Ala
Ile Gln Lys Arg Leu Thr Ile His Gly Lys Glu Asp Glu225
230 235 240Val Ser Pro Tyr Asp Tyr Val
Leu Gln Val Ser Gly Arg Val Glu Tyr 245
250 255Val Phe Gly Asp His Pro Leu Ile Gln Phe Gln Tyr
Ile Arg Asn Cys 260 265 270Val
Met Asn Arg Ala Leu Pro His Phe Ile Leu Val Glu Cys Cys Lys 275
280 285Ile Lys Lys Met Tyr Glu Gln Glu Met
Ile Ala Ile Glu Ala Ala Ile 290 295
300Asn Arg Asn Ser Ser Asn Leu Pro Leu Pro Leu Pro Pro Lys Lys Thr305
310 315 320Arg Ile Ile Ser
His Val Trp Glu Asn Asn Asn Pro Phe Gln Ile Val 325
330 335Leu Val Lys Gly Asn Lys Leu Asn Thr Glu
Glu Thr Val Lys Val His 340 345
350Val Arg Ala Gly Leu Phe His Gly Thr Glu Leu Leu Cys Lys Thr Ile
355 360 365Val Ser Ser Glu Val Ser Gly
Lys Asn Asp His Ile Trp Asn Glu Pro 370 375
380Leu Glu Phe Asp Ile Asn Ile Cys Asp Leu Pro Arg Met Ala Arg
Leu385 390 395 400Cys Phe
Ala Val Tyr Ala Val Leu Asp Lys Val Lys Thr Lys Lys Ser
405 410 415Thr Lys Thr Ile Asn Pro Ser
Lys Tyr Gln Thr Ile Arg Lys Ala Gly 420 425
430Lys Val His Tyr Pro Val Ala Trp Val Asn Thr Met Val Phe
Asp Phe 435 440 445Lys Gly Gln Leu
Arg Thr Gly Asp Ile Ile Leu His Ser Trp Ser Ser 450
455 460Phe Pro Asp Glu Leu Glu Glu Met Leu Asn Pro Met
Gly Thr Val Gln465 470 475
480Thr Asn Pro Tyr Thr Glu Asn Ala Thr Ala Leu His Val Lys Phe Pro
485 490 495Glu Asn Lys Lys Gln
Pro Tyr Tyr Tyr Pro Pro Phe Asp Lys Ile Ile 500
505 510Glu Lys Ala Ala Glu Ile Ala Ser Ser Asp Ser Ala
Asn Val Ser Ser 515 520 525Arg Gly
Gly Lys Lys Phe Leu Pro Val Leu Lys Glu Ile Leu Asp Arg 530
535 540Asp Pro Leu Ser Gln Leu Cys Glu Asn Glu Met
Asp Leu Ile Trp Thr545 550 555
560Leu Arg Gln Asp Cys Arg Glu Ile Phe Pro Gln Ser Leu Pro Lys Leu
565 570 575Leu Leu Ser Ile
Lys Trp Asn Lys Leu Glu Asp Val Ala Gln Leu Gln 580
585 590Ala Leu Leu Gln Ile Trp Pro Lys Leu Pro Pro
Arg Glu Ala Leu Glu 595 600 605Leu
Leu Asp Phe Asn Tyr Pro Asp Gln Tyr Val Arg Glu Tyr Ala Val 610
615 620Gly Cys Leu Arg Gln Met Ser Asp Glu Glu
Leu Ser Gln Tyr Leu Leu625 630 635
640Gln Leu Val Gln Val Leu Lys Tyr Glu Pro Phe Leu Asp Cys Ala
Leu 645 650 655Ser Arg Phe
Leu Leu Glu Arg Ala Leu Gly Asn Arg Arg Ile Gly Gln 660
665 670Phe Leu Phe Trp His Leu Arg Ser Glu Val
His Ile Pro Ala Val Ser 675 680
685Val Gln Phe Gly Val Ile Leu Glu Ala Tyr Cys Arg Gly Ser Val Gly 690
695 700His Met Lys Val Leu Ser Lys Gln
Val Glu Ala Leu Asn Lys Leu Lys705 710
715 720Thr Leu Asn Ser Leu Ile Lys Leu Asn Ala Val Lys
Leu Asn Arg Ala 725 730
735Lys Gly Lys Glu Ala Met His Thr Cys Leu Lys Gln Ser Ala Tyr Arg
740 745 750Glu Ala Leu Ser Asp Leu
Gln Ser Pro Leu Asn Pro Cys Val Ile Leu 755 760
765Ser Glu Leu Tyr Val Glu Lys Cys Lys Tyr Met Asp Ser Lys
Met Lys 770 775 780Pro Leu Trp Leu Val
Tyr Asn Asn Lys Val Phe Gly Glu Asp Ser Val785 790
795 800Gly Val Ile Phe Lys Asn Gly Asp Asp Leu
Arg Gln Asp Met Leu Thr 805 810
815Leu Gln Met Leu Arg Leu Met Asp Leu Leu Trp Lys Glu Ala Gly Leu
820 825 830Asp Leu Arg Met Leu
Pro Tyr Gly Cys Leu Ala Thr Gly Asp Arg Ser 835
840 845Gly Leu Ile Glu Val Val Ser Thr Ser Glu Thr Ile
Ala Asp Ile Gln 850 855 860Leu Asn Ser
Ser Asn Val Ala Ala Ala Ala Ala Phe Asn Lys Asp Ala865
870 875 880Leu Leu Asn Trp Leu Lys Glu
Tyr Asn Ser Gly Asp Asp Leu Asp Arg 885
890 895Ala Ile Glu Glu Phe Thr Leu Ser Cys Ala Gly Tyr
Cys Val Ala Ser 900 905 910Tyr
Val Leu Gly Ile Gly Asp Arg His Ser Asp Asn Ile Met Val Lys 915
920 925Lys Thr Gly Gln Leu Phe His Ile Asp
Phe Gly His Ile Leu Gly Asn 930 935
940Phe Lys Ser Lys Phe Gly Ile Lys Arg Glu Arg Val Pro Phe Ile Leu945
950 955 960Thr Tyr Asp Phe
Ile His Val Ile Gln Gln Gly Lys Thr Gly Asn Thr 965
970 975Glu Lys Phe Gly Arg Phe Arg Gln Cys Cys
Glu Asp Ala Tyr Leu Ile 980 985
990Leu Arg Arg His Gly Asn Leu Phe Ile Thr Leu Phe Ala Leu Met Leu
995 1000 1005Thr Ala Gly Leu Pro Glu Leu
Thr Ser Val Lys Asp Ile Gln Tyr Leu 1010 1015
1020Lys Asp Ser Leu Ala Leu Gly Lys Ser Glu Glu Glu Ala Leu Lys
Gln1025 1030 1035 1040Phe Lys
Gln Lys Phe Asp Glu Ala Leu Arg Glu Ser Trp Thr Thr Lys
1045 1050 1055Val Asn Trp Met Ala His Thr
Val Arg Lys Asp Tyr Arg Ser 1060 1065
1070
User Contributions:
comments("1"); ?> comment_form("1"); ?>Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
Usenet FAQ Index |
Documents |
Other FAQs |
User Contributions:
Comment about this patent or add new information about this topic: